MXPA00011184A - Thienopyridine compounds, their production and use - Google Patents
Thienopyridine compounds, their production and useInfo
- Publication number
- MXPA00011184A MXPA00011184A MXPA/A/2000/011184A MXPA00011184A MXPA00011184A MX PA00011184 A MXPA00011184 A MX PA00011184A MX PA00011184 A MXPA00011184 A MX PA00011184A MX PA00011184 A MXPA00011184 A MX PA00011184A
- Authority
- MX
- Mexico
- Prior art keywords
- substituted
- group
- compound
- salt
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 239
- 238000004519 manufacturing process Methods 0.000 title claims description 62
- 239000002175 thienopyridine Substances 0.000 title description 3
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 claims abstract description 16
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims abstract description 16
- 230000003042 antagnostic Effects 0.000 claims abstract description 14
- 230000001419 dependent Effects 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 239000003163 gonadal steroid hormone Substances 0.000 claims abstract description 8
- -1 amino, benzyloxycarbonylamino Chemical group 0.000 claims description 107
- 239000011780 sodium chloride Substances 0.000 claims description 91
- 150000003839 salts Chemical class 0.000 claims description 71
- 125000001424 substituent group Chemical group 0.000 claims description 68
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 27
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 25
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 23
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims description 15
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000004423 acyloxy group Chemical group 0.000 claims description 12
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims description 7
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 7
- 206010006187 Breast cancer Diseases 0.000 abstract description 5
- 208000006155 Precocious Puberty Diseases 0.000 abstract description 5
- 206010060862 Prostate cancer Diseases 0.000 abstract description 5
- 201000009273 endometriosis Diseases 0.000 abstract description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 4
- 210000001672 Ovary Anatomy 0.000 abstract description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract description 4
- 206010046766 Uterine cancer Diseases 0.000 abstract description 4
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract description 4
- 206010000496 Acne Diseases 0.000 abstract description 3
- 206010001928 Amenorrhoea Diseases 0.000 abstract description 3
- 208000000509 Infertility Diseases 0.000 abstract description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract description 3
- 201000000736 amenorrhea Diseases 0.000 abstract description 3
- 231100000540 amenorrhea Toxicity 0.000 abstract description 3
- 230000002254 contraceptive Effects 0.000 abstract description 3
- 239000003433 contraceptive agent Substances 0.000 abstract description 3
- 230000036512 infertility Effects 0.000 abstract description 3
- 231100000535 infertility Toxicity 0.000 abstract description 3
- 230000035935 pregnancy Effects 0.000 abstract description 3
- 201000010874 syndrome Diseases 0.000 abstract description 3
- 210000004914 menses Anatomy 0.000 abstract description 2
- 230000005906 menstruation Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 79
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- 239000002904 solvent Substances 0.000 description 53
- 230000002829 reduced Effects 0.000 description 51
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 50
- 238000001816 cooling Methods 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 40
- 238000003756 stirring Methods 0.000 description 38
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 101700067048 CDC13 Proteins 0.000 description 27
- 239000000741 silica gel Substances 0.000 description 26
- 229910002027 silica gel Inorganic materials 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 238000000921 elemental analysis Methods 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 24
- 239000000843 powder Substances 0.000 description 23
- 239000012044 organic layer Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 238000004587 chromatography analysis Methods 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000010410 layer Substances 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- 239000000284 extract Substances 0.000 description 16
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- 229940088597 Hormone Drugs 0.000 description 14
- 239000005556 hormone Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 238000007792 addition Methods 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 210000004027 cells Anatomy 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 229940032147 Starch Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- MGEVGECQZUIPSV-UHFFFAOYSA-N BOP reagent Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 MGEVGECQZUIPSV-UHFFFAOYSA-N 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 5
- 229960004338 Leuprorelin Drugs 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002335 preservative Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 102000008238 LHRH Receptors Human genes 0.000 description 4
- 108010021290 LHRH Receptors Proteins 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N Sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 239000000601 hypothalamic hormone Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000001184 potassium carbonate Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 3
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 3
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 3
- 229940043650 HYPOTHALAMIC HORMONES Drugs 0.000 description 3
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 3
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- WKFJWRAGKMPFFR-UHFFFAOYSA-N N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-3-hydroxy-2-methylpropanamide Chemical compound C1=2SC(C=3C=CC(NC(=O)C(C)CO)=CC=3)=C(CN(C)CC=3C=CC=CC=3)C=2C(=O)C(C(=O)C(C)C)=CN1CC1=C(F)C=CC=C1F WKFJWRAGKMPFFR-UHFFFAOYSA-N 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 3
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 230000001817 pituitary Effects 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- WKFJWRAGKMPFFR-HSZRJFAPSA-N (2R)-N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-3-hydroxy-2-methylpropanamide Chemical compound C1=2SC(C=3C=CC(NC(=O)[C@H](C)CO)=CC=3)=C(CN(C)CC=3C=CC=CC=3)C=2C(=O)C(C(=O)C(C)C)=CN1CC1=C(F)C=CC=C1F WKFJWRAGKMPFFR-HSZRJFAPSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WFWKNGZODAOLEO-UHFFFAOYSA-N 1-(4-methoxyphenyl)propan-2-one Chemical compound COC1=CC=C(CC(C)=O)C=C1 WFWKNGZODAOLEO-UHFFFAOYSA-N 0.000 description 2
- UAWVMPOAIVZWFQ-UHFFFAOYSA-N 1-(chloromethyl)-2-methoxybenzene Chemical compound COC1=CC=CC=C1CCl UAWVMPOAIVZWFQ-UHFFFAOYSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XNINAOUGJUYOQX-UHFFFAOYSA-M 2-cyanobutanoate Chemical compound CCC(C#N)C([O-])=O XNINAOUGJUYOQX-UHFFFAOYSA-M 0.000 description 2
- ZPVXSDAYZWUAGC-UHFFFAOYSA-N 2H-thieno[2,3-b]pyridin-4-one Chemical compound O=C1C=CN=C2SCC=C12 ZPVXSDAYZWUAGC-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229940009456 Adriamycin Drugs 0.000 description 2
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- IQXXEPZFOOTTBA-UHFFFAOYSA-N Benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960004926 Chlorobutanol Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N Diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NWNSIURBDQNMCZ-UHFFFAOYSA-N N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-1-hydroxycyclopropane-1-carboxamide Chemical compound C1=2SC(C=3C=CC(NC(=O)C4(O)CC4)=CC=3)=C(CN(C)CC=3C=CC=CC=3)C=2C(=O)C(C(=O)C(C)C)=CN1CC1=C(F)C=CC=C1F NWNSIURBDQNMCZ-UHFFFAOYSA-N 0.000 description 2
- XIKLJIKFVNUIBL-UHFFFAOYSA-N N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-2-hydroxy-2-methylpropanamide Chemical compound C1=2SC(C=3C=CC(NC(=O)C(C)(C)O)=CC=3)=C(CN(C)CC=3C=CC=CC=3)C=2C(=O)C(C(=O)C(C)C)=CN1CC1=C(F)C=CC=C1F XIKLJIKFVNUIBL-UHFFFAOYSA-N 0.000 description 2
- RVNVFYMCQNHMPG-UHFFFAOYSA-N N-[4-[5-benzoyl-3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-1-hydroxycyclopropane-1-carboxamide Chemical compound C=1C=CC=CC=1CN(C)CC(C=1C(=O)C(C(=O)C=2C=CC=CC=2)=C2)=C(C=3C=CC(NC(=O)C4(O)CC4)=CC=3)SC=1N2CC1=C(F)C=CC=C1F RVNVFYMCQNHMPG-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N Phenethyl alcohol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N Phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- ANRQGKOBLBYXFM-UHFFFAOYSA-M Phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 2
- BWSDNRQVTFZQQD-AYVHNPTNSA-N Phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N Phosphorus pentoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 210000004198 Pituitary Gland, Anterior Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960003604 Testosterone Drugs 0.000 description 2
- QGYXCSSUHCHXHB-UHFFFAOYSA-M Thallium(I) hydroxide Chemical compound [OH-].[Tl+] QGYXCSSUHCHXHB-UHFFFAOYSA-M 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 2
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000036231 pharmacokinetics Effects 0.000 description 2
- 108010072906 phosphoramidon Proteins 0.000 description 2
- 229920001888 polyacrylic acid Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000002483 superagonistic Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 229910021515 thallium hydroxide Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VHLBPPIUDAUUFY-UHFFFAOYSA-N (1-carbonochloridoylcyclopropyl) acetate Chemical compound CC(=O)OC1(C(Cl)=O)CC1 VHLBPPIUDAUUFY-UHFFFAOYSA-N 0.000 description 1
- WLPQCHKXJRHZRI-UHFFFAOYSA-N (2-hydroxybenzoyl) 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC(=O)C1=CC=CC=C1O WLPQCHKXJRHZRI-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- HEBZDMGBNDVUAL-UHFFFAOYSA-N (3-chloro-2-methyl-3-oxopropyl) acetate Chemical compound ClC(=O)C(C)COC(C)=O HEBZDMGBNDVUAL-UHFFFAOYSA-N 0.000 description 1
- RLUJIDSXQSEFIP-UHFFFAOYSA-N 1-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-1-methoxyurea Chemical compound C1=CC(N(C(N)=O)OC)=CC=C1C1=C(CN(C)CC=2C=CC=CC=2)C(C(=O)C(C(=O)C(C)C)=CN2CC=3C(=CC=CC=3F)F)=C2S1 RLUJIDSXQSEFIP-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- LSXJPJGBWSZHTM-UHFFFAOYSA-N 2-(bromomethyl)-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1CBr LSXJPJGBWSZHTM-UHFFFAOYSA-N 0.000 description 1
- WJYAJBDKANFOID-UHFFFAOYSA-N 2-(dodecylamino)propanoic acid Chemical compound CCCCCCCCCCCCNC(C)C(O)=O WJYAJBDKANFOID-UHFFFAOYSA-N 0.000 description 1
- YIFCWYUSYGFFMH-UHFFFAOYSA-N 2-(ethoxymethylidene)propanedioic acid Chemical compound CCOC=C(C(O)=O)C(O)=O YIFCWYUSYGFFMH-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-Methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- SHFNREFETDKOIF-UHFFFAOYSA-N 2-hydroxycyclopropane-1-carboxylic acid Chemical compound OC1CC1C(O)=O SHFNREFETDKOIF-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- AXUQUFLXXGKUCJ-UHFFFAOYSA-N 3-(bromomethyl)-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-2-(4-nitrophenyl)thieno[2,3-b]pyridin-4-one Chemical compound C1=2SC(C=3C=CC(=CC=3)[N+]([O-])=O)=C(CBr)C=2C(=O)C(C(=O)C(C)C)=CN1CC1=C(F)C=CC=C1F AXUQUFLXXGKUCJ-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N 3-acetyl-6-methylpyran-2,4-dione Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N Chloroformic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N Diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
- 229940101029 Dipotassium Glycyrrhizinate Drugs 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- KEDPUQKUZHYBGW-UHFFFAOYSA-P F[P-](F)(F)(F)(F)F.[H+].[PH4+] Chemical compound F[P-](F)(F)(F)(F)F.[H+].[PH4+] KEDPUQKUZHYBGW-UHFFFAOYSA-P 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 210000003191 Femoral Vein Anatomy 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 229960002913 Goserelin Drugs 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 210000003016 Hypothalamus Anatomy 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N Isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229940057428 LACTOPEROXIDASE Drugs 0.000 description 1
- 102000028880 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 229940040129 Luteinizing Hormone Drugs 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 229940091250 Magnesium supplements Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- WZGZPAJSVLJZKG-UHFFFAOYSA-N N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-3-hydroxy-3-methylbutanamide Chemical compound C1=2SC(C=3C=CC(NC(=O)CC(C)(C)O)=CC=3)=C(CN(C)CC=3C=CC=CC=3)C=2C(=O)C(C(=O)C(C)C)=CN1CC1=C(F)C=CC=C1F WZGZPAJSVLJZKG-UHFFFAOYSA-N 0.000 description 1
- RKOZBCHRMRTGBD-UHFFFAOYSA-N N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]cyclopropanecarboxamide Chemical compound C1=2SC(C=3C=CC(NC(=O)C4CC4)=CC=3)=C(CN(C)CC=3C=CC=CC=3)C=2C(=O)C(C(=O)C(C)C)=CN1CC1=C(F)C=CC=C1F RKOZBCHRMRTGBD-UHFFFAOYSA-N 0.000 description 1
- KRGNFQOLOCUNAL-UHFFFAOYSA-N N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(4-fluorobenzoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1CN(C)CC(C=1C(=O)C(C(=O)C=2C=CC(F)=CC=2)=C2)=C(C=3C=CC(NC(=O)C4CC4)=CC=3)SC=1N2CC1=C(F)C=CC=C1F KRGNFQOLOCUNAL-UHFFFAOYSA-N 0.000 description 1
- SCVUMXDOOFQQCN-UHFFFAOYSA-N N-[4-[5-benzoyl-3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-3-hydroxy-2-methylpropanamide Chemical compound C1=CC(NC(=O)C(CO)C)=CC=C1C1=C(CN(C)CC=2C=CC=CC=2)C(C(=O)C(C(=O)C=2C=CC=CC=2)=CN2CC=3C(=CC=CC=3F)F)=C2S1 SCVUMXDOOFQQCN-UHFFFAOYSA-N 0.000 description 1
- QWLISCJHYITNQF-UHFFFAOYSA-N N-methoxy-1-phenylmethanamine Chemical compound CONCC1=CC=CC=C1 QWLISCJHYITNQF-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N N-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 229940037525 NASAL PREPARATIONS Drugs 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940116315 Oxalic Acid Drugs 0.000 description 1
- 229950003180 PEPLOMYCIN Drugs 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 210000003635 Pituitary Gland Anatomy 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229940093429 Polyethylene Glycol 6000 Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229960003975 Potassium Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038001 Rebound effect Diseases 0.000 description 1
- 229940083542 Sodium Drugs 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N Trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229960004824 Triptorelin Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl] Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001488 breeding Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- LFSYFYDEAHJBAU-UHFFFAOYSA-N diethyl 2-[amino-[3-ethoxycarbonyl-5-(4-methoxyphenyl)-4-methylthiophen-2-yl]methylidene]propanedioate Chemical compound CCOC(=O)C1=C(C(N)=C(C(=O)OCC)C(=O)OCC)SC(C=2C=CC(OC)=CC=2)=C1C LFSYFYDEAHJBAU-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- MVSLPTXAIZOIBD-UHFFFAOYSA-N ethyl 2-amino-5-(4-methoxyphenyl)-4-methylthiophene-3-carboxylate Chemical compound CCOC(=O)C1=C(N)SC(C=2C=CC(OC)=CC=2)=C1C MVSLPTXAIZOIBD-UHFFFAOYSA-N 0.000 description 1
- WIVNPGXPJBBZQH-UHFFFAOYSA-N ethyl 2-amino-5-phenylthiophene-3-carboxylate Chemical compound S1C(N)=C(C(=O)OCC)C=C1C1=CC=CC=C1 WIVNPGXPJBBZQH-UHFFFAOYSA-N 0.000 description 1
- ZOQDKVSJEVCQKH-UHFFFAOYSA-N ethyl 3-methyl-2-(4-nitrophenyl)-4-oxo-7H-thieno[2,3-b]pyridine-5-carboxylate Chemical compound CC=1C2=C(O)C(C(=O)OCC)=CN=C2SC=1C1=CC=C([N+]([O-])=O)C=C1 ZOQDKVSJEVCQKH-UHFFFAOYSA-N 0.000 description 1
- JQBYSHAAGDBSKA-UHFFFAOYSA-N ethyl 4-methyl-2-[(4-methyl-3-oxopent-1-enyl)amino]-5-phenylthiophene-3-carboxylate Chemical compound S1C(NC=CC(=O)C(C)C)=C(C(=O)OCC)C(C)=C1C1=CC=CC=C1 JQBYSHAAGDBSKA-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 229940121381 gonadotrophin releasing hormone (GnRH) antagonists Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;N-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;O-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 108010080415 lecirelin Proteins 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- VWUPQQFMCOQIEJ-UHFFFAOYSA-M potassium;hydrogen carbonate;hydrate Chemical compound O.[K+].OC([O-])=O VWUPQQFMCOQIEJ-UHFFFAOYSA-M 0.000 description 1
- BYTCDABWEGFPLT-UHFFFAOYSA-L potassium;sodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[K+] BYTCDABWEGFPLT-UHFFFAOYSA-L 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- GGKLADJTQDGVBP-UHFFFAOYSA-M sodium;propane-1,2,3-triol;chloride Chemical compound [Na+].[Cl-].OCC(O)CO GGKLADJTQDGVBP-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical class C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229910001929 titanium oxide Inorganic materials 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AXFYFNCPONWUHW-UHFFFAOYSA-N β-Hydroxy β-methylbutyric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 1
Abstract
The compound of the present invention possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful for preventing or treating sex hormone-dependent diseases, e.g. , sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, breast cancer, pituitary tumor), prostatic hypertrophy, hysteromyoma, endometriosis, precocious puberty, amenorrhea syndrome, multilocular ovary syndrome, pimples etc., or as a pregnancy regulator (e.g., contraceptive), infertility remedy or menstruation regulator.
Description
DESCRIPTION Thienopyridine Compounds, Their Production and Use
TECHNICAL FIELD The present invention relates to thieno [2, 3-b] pyridine derivatives, which exhibit antagonistic activity to gonadotropin releasing hormone (GnRH), its production and use.
BACKGROUND TECHNIQUE The secretion of the hormone of the hypophysial anterior lobe is regulated by the peripheral hormone secreted by each target organ and the promotion of the secretion or suppression of the secretion of the hormone secreted by the hypothalamus, which is the superior center to the anterior lobe. pituitary, and this group of hormones will be referred to hereinafter to this group of hormones as hypothalamic hormone in this specification. To date, nine hypothalamic hormones have been identified, for example, the hormone releasing the thyroid stimulating hormone (THR), and the gonadotropin releasing hormone [GnHR, also known as the hormone releasing the luteinizing hormone (LH-RH)], etc. It is surmised that these hypothalamic hormones exhibit their
Ref. No. 124427 hormonal actions, etc. via receptors that are added are present in the anterior hypophysial lobe, and are underway, analysis of specific receptor genes for these hormones, including humans. Antagonists or agonists that act specifically and selectively on these receptors, should therefore regulate the action of the hypothalamic hormones and, therefore, regulate the secretion of the hormone of the anterior hypophysial lobe. As a result, it is expected that such antagonists or agonists, prevent or treat diseases that depend on this hormone of the anterior hypophysial lobe.
Known compounds possessing GnRH-antagonistic activity include linear peptides derived from GnHR (USP 5,140,009 and USP 5, 171,835), a cyclic hexapeptide derivative (JP-A-61-191698), a bicyclic peptide derivative [ Journal of Medicinal Chemistry, Vol. 36, pp. 3265-3273 (1993)], and so on. Non-peptide compounds, which possess GnRH antagonizing activity, include the compounds described in WO 95/28405, WO 97/14697, WO 97/14682, WO 97/41126 and so on.
Peptide compounds have a large number of problems to be solved, with respect to ABSORBABILITY, dosage form, dosage volume, drug stability, sustained action, metabolic stability, etc. There is a strong demand for an oral GnRH antagonist, especially one based on a non-peptide compound, which has an excellent therapeutic effect on hormone-dependent cancers, for example prostate cancer, endometriosis, precocious puberty, etc. And that they do not show transitory hypophysial gonadotropic action (acute action).
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a diagrammatic representation of the relieving effect of the suppression of LH plasma concentrations in castrated monkeys, after oral administration of the compound of the following Example 1-2, in which ••••• •• represents the control (1) (vehicle), ••• ••• represents the control (2) (vehicle), ... [3 ... represents the control (3) (vehicle), -p- represents the compound (1) [the test administered to the animal the compound of Ex. No. 1-2] and -p- represents the compound (2) [the test compound administered to the animal, the compound of ex. No. 1-2].
DESCRIPTION OF THE INVENTION The present inventors produced various thienopyridine derivatives, investigated their action, and found that some compounds possess excellent GnRH antagonizing activity. The inventors have conducted other investigations based on these discoveries, and developed the present invention.
Accordingly, the present invention relates to: [1] a compound of the formula:
wherein R1 represents an alkyl group of C? -, which may be substituted, a cycloalkyl group of C3-, which may be substituted, an alkoxyamino group of C? _6, which may be substituted or a hydroxyamino group, which may be substituted; and R2 represents an alkyl group of O.- ?, which may be substituted or a phenyl group, which may be substituted; When R1 is an unsubstituted C1-7 alkyl group, then R2 is a C1-7 alkyl group or a substituted phenyl group, or a salt thereof [sometimes called hereafter for brevity as the compound (I) ]: [2] a compound of (I) above or a salt thereof, wherein R1 is (1) a C1-7 alkyl group, which may be substituted by 1 to 5 substituents selected from the group consisting of (i) hydroxy, (ii) C 1-7 acyloxy, (iii) amino, which may be substituted by 1 or 2 substituents selected from the group consisting of C 1-6 alkoxycarbonyl, benzyloxycarbonyl, C 1-3 acyl , C 1 -C 3 alkylsulfonyl and C 1 -C 3 alkyl, (iv) C 1-10 alkoxy, which may be substituted by 1 to 3 secstituted substituents of the group consisting of C 3 7 cycloalkyloxycarbonyl and C 1 -C 7 alkoxy 3 and (v) C? -6-carbonyl alkoxy, (2) a C3-7 cycloalkyl group, which may be substituted by 1 to 3 substituents selected from the group consisting of (i) hydroxy, (ii) C? _7 acyloxy, (iii) amino, which may be substituted by 1 or 2 substituents selected from the group consisting of C?-6-carbonyl alkoxy, benzyloxycarbonyl, C ac acyl? _3, C ?_3 alkylsulfonyl and C ?_alkyl, (iv) C 1-10 alkoxy, which may be substituted by 1 to 3 substituents selected from the group consisting of C 3-7 cycloalkyloxy-carbonyl and C-alkoxy; -3 and (v) C6-6-carbonyl alkoxy, (3) an alkoxyamino group of C6-6, which may be substituted by 1 to 5 substituents selected from the group consisting of (i) hydroxy, (ii) ) C 1-7 acyloxy, (iii) amino, which may be substituted by 1 or 2 substituents selected from the group consisting of C?-6-carbonyl alkoxy, benzyloxycarbonyl, C 1-3 acyl, C 1-3 alkylsulfonyl and C 1 -3 alkyl, (iv) C 1 0 alkoxy, which may be substituted by 1 to 3 substituents selected from the group consisting of C 3 7 -carbonyl cycloalkyloxy and C 1-3 alkoxy and (v) C6-6-carbonyl alkoxy, or (4) a hydroxyamino group, which may be substituted by 1 or 2 substituents selected from the group consisting of (i) C1-7 acyloxy, (ii) amino, which may be substituted by 1 or 2 substituents selected from the group consisting of C6-C6-alkynyl, benzyloxycarbonyl, C1-3 acyl, C1-3 alkylsulfonyl and C3_3 alkyl, (iii) alkoxy C1-10, which may be substituted by 1 to 3 substituents selected from the group consisting of C3-7-cycloalkyloxycarbonyl and C1-3alkoxy and (iv) C6-6alkyl; and R2 is (1) an alkyl group of C7_7 which may be substituted by 1 to 5 substituents selected from the group consisting of (i) hydroxy, (ii) C1-7 acyloxy, (iii) amino, to which it may be substituted by 1 or 2 substituents selected from the group consisting of C?-6-carbonyl alkoxy, benzyloxycarbonyl, C?-3 acyl, C 1-3 alkylsulfonyl and C? _3 alkyl, (iv) C 1 - alkoxy 10, which may be substituted by 1 to 3 substituents selected from the group consisting of C3-7-cycloalkyloxy-carbonyl and C1-3.alkoxy and (v) Ci-β-carbonyl-alkoxy, or (2) a group phenyl, which may be substituted by 1 to 5 substituents selected from the group consisting of halogen, C 1-3 alkyl and C 1 -3 alkoxy; [3] a compound of (1) above or a salt thereof, wherein R1 is a C1-7 alkyl group, which may be substituted or a C3-7 cycloalkyl group, which may be substituted; [4] a compound of (1) above or a salt thereof, wherein R1 is a substituted, branched C3-7 alkyl group or a substituted C3-7 cycloalkyl group; [5] a compound of (1) above or a salt thereof, wherein R1 is an alkyl group of C? -? substituted by hydroxy, or a C3-7 cycloalkyl group substituted by hydroxy;
[6] a compound of (1) above or a salt thereof, wherein R1 is a substituted C3-7 cycloalkyl group; [7] a compound of (1) above or a salt thereof, wherein R1 is a cyclopropyl group, which may be substituted by hydroxy; [8] a compound of (1) above or a salt thereof, wherein R2 is a branched C3_7 alkyl group, which may be substituted; [9] a compound of (1) above or a salt thereof, wherein R2 is a phenyl group, which may be substituted; [10] a compound of (1) above or a salt thereof, wherein Rz is a phenyl group; [11] a compound of (1) above or a salt thereof, wherein R1 is a cycloalkyl group of C3-7 and R2 is an alkyl group of C? -6, '[12] a compound of (1) above or a salt thereof, wherein R1 is (1) a C1-4 alkyl group, substituted 1 or 2 hydroxy, (2) a C3_7 cycloalkyl group substituted by hydroxy, or (3) an alkoxyamino group of C ?-3; Y
R2 is an isopropyl group or a phenyl group; [13] a compound of (1) above or a salt thereof, wherein R1 is (1) a C1-7 alkyl group, which may be substituted by i2 substituents selected from the group consisting of hydroxy, alkylcarbonyl of C? -3, amino, benzyloxycarbonylamino, C? _3 alkoxy, C? _3 alkoxy-C1-3 alkoxy and C? -3-carbonyl alkoxy, (2) a C3-7 cycloalkyl group, which may be substituted by a hydroxy or a C 1 -3-carbonyloxy alkyl, or (3) an alkoxyamino group of C 3 -3; and Rz is (1) an isopropyl group, which may be substituted by a hydroxy or (2) a phenyl group; [14] 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- (4-cyclopropanecarbonylaminophenyl) -4-oxothiene [2, 3 -b] pyridine or a salt thereof; [15] 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- [4- (3-hydroxy-2-methylpropionylamino) phenyl ] -4-oxothieno [2, 3-b] pyridine or a salt thereof; [16] 3- (N-Benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- [4- [(1-hydroxycyclopropyl) carbonylamino] phenyl] -4-oxothieno [2, 3-b] pyridine or a salt thereof; [17] 3- (N-Benzyl-N-methylaminomethyl) -5-benzoyl-7- (2,6-difluorobenzyl) -4,7-dihydro-2- [4- [(1-hydroxycyclopropyl) carbonylamino] phenyl] -4-oxothieno [2, 3-b] pyridine or a salt thereof; [18] a process for the production of a compound of [1] above or a salt thereof, which comprises the reaction of a compound of the formula:
wherein R2 represents an alkyl group of C? _7, which may be substituted or a phenyl group, which may be substituted, or a salt thereof [sometimes called for brevity as compound (II)], with i) a compound of the formula: RlaC00H wherein Rla represents an alkyl group of C? _7, which may be substituted or a C3-7 cycloalkyl group, which may be substituted, or a salt thereof or a reagent derived therefrom; or ii) carbonyldiimidazole, phosgene or a chloroformate, followed by reaction with a compound of the formula:
RlbH wherein R 1b represents an alkoxyamino group of C 6 -6, which may be substituted or a hydroxyamino group, which may be substituted, or a salt thereof; [19] a process for the production of a compound of [3] above or a salt thereof, which comprises the reaction of a compound (.II) with a compound of the formula: RlaCOOH wherein Rla represents an alkyl group of C? _7, which may be substituted or a cycloalkyl group, which may be substituted, or a salt thereof or a reagent derived therefrom; [20] a pharmaceutical composition, which comprises a compound of (1) above or a salt thereof; [21] a pharmaceutical composition of (20) above, which is to antagonize gonadotropin releasing hormone; [22] a pharmaceutical composition of (21) above, which is to prevent or treat a sex hormone-dependent disease; [23] a method for antagonizing gonadotropin releasing hormone in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound (1) above or a salt thereof, with a pharmaceutically acceptable excipient, carrier or diluent; [24] the use of a compound (1) above or a salt thereof, for the manufacture of a pharmaceutical composition for antagonizing the gonadotropin releasing hormone, and so on.
Each of the symbols in the formulas above is described hereafter, in more detail.
The "C 1-7 alkyl group" of the "Ci-7 alkyl group, which may be substituted", for R 1 includes, for example, a straight chain C 1-7 alkyl group, such as methyl, ethyl, propyl , butyl, pentyl, hexyl, heptyl, etc .; a branched chain C3_7 alkyl group, such as, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, etc. And so on. Among others, the preferred is a branched C3-7 alkyl group. More preferably it is isopropyl.
The "substituents" of the "C 1-7 alkyl group, which may be substituted", for R 1 include, for example, (i) hydroxy, (ii) C 1-7 acyloxy (e.g., alkylcarbonyloxy) C? -6, such as acetoxy, propionyloxy, etc., benzyloxy, etc.), (iii) amino, which may be substituted by 1 02 substituents selected from the group consisting of C? _6 alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), benzyloxycarbonyl, C ?3 acyl (for example, C? _-carbonyl alkyl such as acetyl, propionyl, etc.), C? _3 alkylsulfonyl (e.g. methanesulfonyl, etc.) and C? -3 alkyl. { for example, methyl, ethyl, etc.), etc. [e.g., amino, methoxycarbonylamino, ethoxycarbonylamino, tert-butoxycarbonylbenzyloxycarbonylamino, acetylamino, methanesulphonylamino, methylamino, dimethylamino, etc.), (iv) Ci -io alkoxy (preferably C? -4), which may be substituted by 1 to 3 substituents selected from the group consisting of C3-7 cycloalkylcarbonyl (e.g., cyclohexylcarbonyloxy, etc.) and C 1-3 alkoxy (e.g., methoxy, ethoxy, etc.) [e.g. methoxy, ethoxy, propoxy, terbutoxy, cyclohexyloxycarbonyloxy-1-ethoxy, methoxymethoxy, ethoxymethoxy, etc.], (v) C? -6-carbonyl alkoxy (eg, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, etc.), and so on . Among others, the preferred one is hydroxy.
The "C 1-7 alkyl group" may have 1 to 5, preferably 1 to 3 substituents as mentioned above, at the possible positions and, when the number of substituents is two or more, these substituents may be the same or different ones of others.
The "C3-7 cycloalkyl group" of the "C3_7 cycloalkyl group, which may be substituted", for R1 includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. Among others, it is preferably cyclopropyl.
The "substituents" of the "C3_7 cycloalkyl group, which may be substituted", for R1, are the same as those mentioned above for the "substituents" of the "C7_7 cycloalkyl group, which may be substituted", for R1. the number of substituents is 1 to 3. when the number of substituents is two or more, those substituents may be the same or different from each other.
The "C6-6 alkoxyamino group" of the "C6-C6 alkoxyamino group, which may be substituted" for R1 includes, for example, C- or β-diaminoalkylamino, (eg, methoxyamino, ethoxyamino) , dimethoxyamino, diethoxyamino, ethoxymethoxyamine, etc.), etc. Among others, the preferred is C 1 -3 mono-alkoxyamino (eg, methoxyamino, etc.).
The "substituents" of the "C 1 -C 6 alkoxyamino group, which may be substituted", for R 1 and its number, are the same as those mentioned for the "substituents" of the C 1-7 alkyl group, which may be substituted "for R1, when the number of substituents is two or more, these substituents may be the same or different from each other: the" C6-6 alkoxy "or the" amino group nitrogen atom "of the Ci-alkoxyamino group -ß, may be replaced by the "substituents" above.
Such "C1-6 alkoxyamino group, which may be substituted" is exemplified by methoxyamino, N-methyl-N-methoxyamino, n-ethyl-N-methoxyamino, ethoxyamino, dimethoxyamino, diethoxyamino, ethoxymethoxyamino, etc. Preferred is C 1-3 alkoxyamino, N-C 1-3 alkyl N-alkoxyamino, etc.
The "substituents" of the hydroxyamino group, which may be substituted "for R1, may be located in the" hydroxy group "of the hydroxyamino group or the" nitrogen atom of an amino group "of the hydroxyamino group. "hydroxy group" include, for example, (i) C1-7 acyloxy (eg, C6-6-carbonyloxy alkyl, such as acetoxy, propionyloxy, etc., benzyloxy, etc.), (ii) amino, which may be substituted by 1 or 2 substituents selected from the group consisting of C6-6-carbonyl alkoxy (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), benzyloxycarbonyl, C1-3 acyl (e.g. , Ci-2-carbonyl alkyl, such as acetyl, propionyl, etc.), C 1-3 alkylsulfonyl, (e.g., methanesulfonyl, etc.) and C 1-3 alkyl (e.g., methyl, ethyl, etc.). ) . etc.
[for example; amino, methoxycarbonylamino, ethoxycarbonylamino, tert-butoxycarbonylbenzyloxycarbonylamino, acetylamino, methanesulfonylamino, methylamino, dimethylamino, etc.], (ii) C 1-10 alkoxy (preferably C 1-4), which may be substituted by 1 to 3 substituents selected from the group consisting of a group consisting of cycloalkyloxycarbonyl of C3-7 (for example, cyclohexyloxycarbonyloxy, etc.) and C1-3alkoxy (for example, methoxy, ethoxy, etc.) [for example; methoxy, ethoxy, propoxy, tert-butoxy, cyclohexyloxycarbonyloxy, methoxymethoxy, ethoxymethoxy, etc.], and so on. The number of substituents is 1 to 5, preferably 1 to 3. When the number of substituents is two or more, those substituents may be the same or different from each other. Such "substituents" on the "amino group nitrogen atom" include, for example, (1) each of the groups described in subparagraphs (i) to (iii) above and (2) C? _6 alkyl ( for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, etc. The number of substituents is from 1 to 5, preferably from 1 to 3. When the number of substituents is two or more, these substituents may be the same or different from each other.
Preferred examples of the "hydroxyamino group, which may be substituted" include N-alkyl-6-N-hydroxyamino-alkyl (eg, N-methyl-N-hydroxyamino, N-ethyl-N-hydroxyamino, etc.) and so on The most preferred is N-alkyl of C1- .3-N-hydroxyamino, etc.
The "C? _7 alkyl group" of the "Ci-7 alkyl group, which may be substituted" for R2 includes, for example, an alkyl group of C? -? straight or branched chain, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, etc. Among others, the preferred is C1-3 alkyl (eg, methyl, ethyl, propyl, isopropyl, etc.). The most preferred is isopropyl.
The "substituents" of the "C" _7 alkyl group which may be substituted "by R2 and their number are the same as those mentioned above for the" substituents "of the" C1_7 alkyl group, which may be substituted " for R1. When the number of substituents is two or more, these substituents may be the same or different from each other.
The "substituents" of the "phenyl group, which may be substituted" for R 2, include, for example, halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), C 1-3 alkyl (e.g., methyl) , ethyl, propyl, isopropyl, etc.), C1-3 alkoxy (eg, methoxy, ethoxy, propoxy, isopropoxy, etc.), etc. Among others, the preferred one is halogen, the most preferred being fluorine.
The "phenyl group" may have from 1 to 5, preferably from 1 to 3 s, as mentioned above, in the possible positions and, when the number of substituents is two or more, those substituents may be the same or different ones. of others.
R1 is preferably a substituted, branched C3_7 alkyl group or a substituted C3-7 cycloalkyl group, more preferably a C7_7 alkyl group substituted by hydroxy or a C3_7 cycloalkyl group, substituted by hydroxy. Among others, the preferred one is a C3-7 cycloalkyl group, substituted. Also, an alkyl group of C? -3 / which may be substituted by hydroxy, a C3-7 cycloalkyl group, which may be substituted by a hydroxy, C1-3 mono-alkoxyamino, C1- N-alkyl 3-N-hydroxyamino, hydroxyamino, is preferred.
Especially preferred R1 is (i) cyclopropyl, which may be substituted by a hydroxy or (ii) methoxyamino, etc. The most preferred is cyclopropyl, which may be substituted by a hydroxy group.
R 2 is preferably a C 1-7 alkyl group, which may be substituted. Most preferred is a C1-3 alkyl group, which may be substituted by a hydroxy group. Isopropyl is especially preferred. Phenyl is also preferred.
Preferred examples of the compound (I), include a compound wherein, R 1 is an alkyl group of C 3 -3 / which may be substituted by a hydroxy group, a C 3-7 cycloalkyl group, which may be substituted by a hydroxy group or a mono-alkoxyamino group of C? -3; and R2 is an alkyl group of C? -3 or a salt thereof.
The most preferred is a compound, wherein, R1 is
(1) an alkyl group of C? -4, substituted by 1 or 2 hydroxy,
(2) a C3-7 cycloalkyl group, substituted by hydroxy, or
(3) a C1-3 alkoxyamino group; and R2 is an isopropyl group or a phenyl group, or a salt thereof.
A compound wherein R 1 is (1) a C 1-7 alkyl group, which may be substituted by 1 or 2 substituents selected from the group consisting of hydroxy, C 3 -carbonyl, amino, benzyloxycarbonylamino, alkoxy, C3-C3-alkoxy and C3-carbonyl-alkoxy, (2) a C3_7 cycloalkyl group, which may be substituted by a hydroxy group or a C3-carbonyloxy alkyl, or (3) a C1-3 alkoxyamino group; and R2 is (1) an isopropyl group, which may be substituted by a hydroxy group or (2) a phenyl group, or a salt thereof, is also preferred.
As compound (I), specifically mentioned are 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- (4-cyclopropanecarbonylaminophenyl) -4 -oxothieno [2, 3-b] pyridine or a salt thereof, 5-benzoyl-3- (N-benzyl-N-methylaminomethyl) -7- (2,6-difluorobenzyl) -4,7-dihydro-4- oxo-2- [4- (3-hydroxy-2-methylpropionylamino) phenyl] thieno [2, 3-b] pyridine, 5- (4-fluorobenzoyl) -3- (N-benzyl-N-methylaminomethyl) -7- (2,6-difluorobenzyl) -4,7-dihydro-4-oxo-2- (4-cyclopropanecarbonylaminophenyl) thieno [2,3-b] pyridine, 3- (N-benzyl-N-methylaminomethyl) -4,7 -dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- [4- (3-hydroxy-2-methylpropionylamino) phenyl] -4-oxothieno [2, 3-b] pyridine, 3- (N -benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- (4-N 1 -methoxyureidophenyl) -4-oxothieno [2,3-b] pyridine, 3- (N-Benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- [4- [(1-hydroxycyclopropyl) carbonylamino] phenyl] - 4-oxothieno [2, 3-b] pyridine, (R) -4,7-dihydro-2- [4- (3-hydroxy-2-methylpropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3 - (N-benzyl-N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2,3-b] pyridine, 4,7-dihydro-2- [4- (2-hydroxy-2-methylpropionylamino) phenyl] - 7- (2,6-difluorobenzyl) -3- (N-benzyl-N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2,3-b] pyridine, 4,7-dihydro-2- [4- ( 3-hydroxy-3-methylbutyrylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N-benzyl-N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine, ( R) -4,4-dihydro-2- [4- (2,3-dihydroxypropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N-benzyl-N-methylaminomethyl) -5-isobutyri-1 4-oxothieno [2, 3-b] pyridine, 3- (N-benzyl-N-methylaminomethyl) -5-benzoyl-7- (2,6-difluorobenzyl) -4,7-dihydro-2- [4- [ (1-hydroxycyclopropyl) carbonylamino] phenyl] -4-oxothieno [2, 3-b] pyridine, and salts thereof.
The compound (I) can be produced in any manner known per se, for example, according to the methods described in WO 95/28405 or methods analogous thereto. Mentioned concretely are, the following Production Method 1 and Production Method 2.
Production method 1: The compound (I) is produced by the reaction of the compound (II) with a compound of the formula, RlaCOOH, where Rla represents a C1-7 alkyl group, which may be substituted or a cycloalkyl group of c3_7, which may be substituted, or a salt thereof or a reagent derived therefrom [sometimes called hereafter, for brevity as compound (III)].
The "C1-7 alkyl group, which may be substituted" and the "C3-7 cycloalkyl group, which may be substituted" for Rla, are the same as those mentioned above for the "C1-7 alkyl group". , which may be substituted "and the" cycloalkyl group of C3-7, which may be substituted "by R1, respectively.
The "derivatized reagent" of the "compound of the formula: RlaCOOH, or a salt thereof or a reagent derived therefrom" includes, for example, a compound of the formula: RlaCOY wherein, Y represents halogen and R is the same as was defined above.
The amount of compound (III) to be subjected to reaction is about 3 moles, relative to one mole of compound (II).
This reaction is also carried out in the presence of a base. The "base" is exemplified by inorganic bases, such as sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium carbonate hydroxide, sodium hydroxide, potassium hydroxide and thallium hydroxide, and organic bases such as triethylamine and pyridine, etc.
The amount of the "base" is about 1 to 10 moles, preferably about 2 to 5 moles, relative to one mole of the compound (II).
In the case where a compound of the formula is used; RlaCOOH or a salt thereof, a condensing reagent is employed, which is generally used in peptide chemistry, such as benzotronazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBop), to form an amide bond.
This reaction is advantageously carried out in a solvent inert to the reaction. Examples of the solvent include ethers (e.g., ethyl ether, dioxane, dimethoxyethane, tetrahydrofuran, etc.), aromatic hydrocarbons (e.g., benzene, toluene, etc.), amides (e.g., dimethylformamide, dimethylacetamide, etc.) . halogenated hydrocarbons (for example, chloroform, dichloromethane, etc.). etc.
The reaction temperature is usually about 0 to 150 ° C, preferably at room temperature (about 15 to 25 ° C). The reaction time is usually around 1 to 12 hours.
The compound (II) can be produced in any manner known per se, for example, by the methods described in WO 95/28405, or methods analogous thereto.
The compound (I) wherein R 1 is an alkoxyamino group of C 6 -6, which may be substituted or a hydroxyamino group, which may be substituted, may be produced according to the method of the following, Production method 2.
Production method 2: The compound (I) is produced by the reaction of the compound (II) with carbonyldiimidazole (N, N'-carbonyldiimidazole; CDI), phosgene (monomer, dimer or trimer) or a chloroformate, followed by the reaction with a compound of the formula: RlbH, wherein Rlb represents an alkoxyamino group of C? -6, which may be substituted or a hydroxyamino group, which may be substituted, or a salt thereof [sometimes called hereafter for brevity as the compound (IV)].
The "chloroformate" includes, for example, a compound of the formula: C1-C00Y ', wherein Y' represents an alkyl group of C? -β, such as ethyl chloroformate, etc.
The "alkoxyamino group of C? _6, which may be substituted" and the "hydroxyamino group, which may be substituted", by Rlb, are the same as those mentioned above for the "C? -6 alkoxyamino group, the which may be substituted "and the" hydroxyamino group, which may be substituted "by R1, respectively.
In the reaction of the compound (II) with carbonyldiimidazole, phosgene or chloroformates, the carbonyldiimidazole, phosgene or the chloroformates are used in an amount of about 1 to 3 moles, relative to one mole of the compound (II).
This reaction is advantageously carried out in a solvent inert to the reaction. Examples of the solvent include ethers (for example ethyl ether, dioxane, dimethoxyethane, tetrahydrofuran, etc.), aromatic hydrocarbons (for example, benzene, toluene, etc.), amides (for example, dimethylformamide, dimethylacetamide, etc.) , halogenated hydrocarbons (for example, chloroform, dichloromethane, etc.), etcetera.
The reaction temperature is usually about 0 to 150 ° C, preferably at room temperature (about 15 to 25 ° C). The reaction time is usually around 1 to 36 hours.
This reaction is also carried out in the presence of a base. The "base" is exemplified by organic bases, such as sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, sodium hydroxide potassium hydroxide and thallium hydroxide and organic bases, such as triethylamine and pyridine, etc.
The amount of the "base" is about 2 to 20 moles, preferably about 5 to 12 moles, relative to one mole of the compound (II).
The following reaction with the compound (IV) can be carried out under the same conditions of the above reaction of the compound (II) with carbonyldiimidazole, phosgene or a chloroformate. The amount of the compound (IV) is from about 2 to 20 moles, preferably from about 5 to 10 moles, relative to one mole of the compound (II).
The reaction temperature is usually around 0 to 150 ° C, preferably at room temperature (about 15 to 25 ° C). The reaction time is usually around 1 to 6 hours.
The compound (I) of the present invention can be isolated and purified by ordinary means of separation, such as recrystallization, distillation and chromatography, etc. When the compound of the formula (I) is obtained in the free form, it can be converted to a salt by methods known per se or methods analogous thereto. When the compound (I) is obtained in the salt form, it can be converted to the free form or to another salt, by methods known per se or methods analogous thereto.
The salts of the compound (I) are preferably the physiologically acceptable acid addition salts. Such salts include, for example, salts with inorganic acids (for example, hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid) and physiologically acceptable acid addition salts with organic acids (for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid). When the compound (I) has an acidic group, it can form a pharmaceutically acceptable salt with an inorganic base (for example, alkali metals, such as sodium, potassium, calcium and magnesium, alkaline earth metals, ammonia) or an organic base (e.g. , trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethylamine, dicyclohexylamine, NN '-dibenzylethylenediamine).
The compound (I) can be a hydrate, or a non-hydrate. The hydrate is exemplified by monohydrates, sesquihydrate and dihydrate.
When the compound (I) is obtained as a mixture
(racemate) of optically active configurations, can be solved to the forms (R) - and (s) - by conventional optical resolution techniques.
The compound (I) of the present invention (hereinafter also referred to as "the compound of the present invention") possesses excellent GnRH antagonizing activity and low toxicity. In short, it is excellent in its oral absorption capacity, its ability to maintain action, stability and pharmacokinetics.
In addition, it can be easily produced. The compound of the present invention can therefore be used safely in a mammal (e.g., human, monkey, bovine, horse, dog, cat, rabbit, rat, mouse) for the prevention and / or treatment of diseases dependent on female hormones, diseases due to excess of these hormones, etc., by suppressing the secretion of gonadotropin, through its antagonistic action of the GnRH receptor to control the concentrations of sex hormones in the blood.
For example, the compound of the present invention is useful for the prevention and / or treatment of sex hormone-dependent cancers (e.g., prostate cancer, uterine cancer, breast cancer, pituitary tumor, etc.), prostatic hypertrophy , hysteromyoma, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, multilocular ovary syndrome, pimples, etc. The compound of the present invention is also useful for the regulation of reproduction in men and women (e.g., pregnancy regulators, menstrual cycle regulators, etc.). The compound of the present invention is also used as a male or female contraceptive, or as an inducer of female ovulation. Based on its rebound effect after being removed, the compound of the present invention can be used to treat infertility.
In sum, the compound of the present invention is useful for the regulation of animal estrus, the improvement of the quality of meat, and the promotion of animal growth in the field of animal husbandry. The compound of the present invention is also useful as a promoter of fish roe deposition.
Although the compound of the present invention can be used alone, it is effective to use it in combination with an antiandrogen agent or an anti-estrogen, non-steroidal or steroidal agent. The compound of the present invention can also be used to suppress the transient rise in blood of testosterone concentrations (spreading phenomenon), observed in the administration of a superagonist, such as Leuprorelin Acetate. The compound of the present invention can be used in combination with a superagonist, such as leuprorelin acetate, gonadrelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterelin, lecirelin, and the like. Among others, the preferred one is leuprorelin acetate. The compound of the present invention can also be used with a chemotherapeutic agent for cancer. A preferred example of such a combination is the compound of the present invention, in combination with chemotherapeutic agents, such as iforpha ida, UTF, adriamycin, peplomycin and cisplatin for prostate cancer. For breast cancer, the compound of the present invention can be used with chemotherapeutic agents, such as cyclophosphamide, 5-FU, UFT, methotrexate, adriamycin, mitomycin C, and mitoxantrone.
When the compound of the present invention is used for the prevention and / or treatment (as a prophylactic and / or a therapeutic agent for) the above mentioned diseases or is used in the field of animal or fish breeding, it can be administered orally or non-orally, when formulated with a pharmaceutically acceptable carrier, usually in the form of solid preparations, such as tablets, granules and powders for oral administration, or in the form of intravenous, subcutaneous, intramuscular or other injections Suppositories or sublingual tablets for non-oral administration. It can also be sublingually, subcutaneously, intramuscularly or otherwise administered in the form of sustained release preparations of sublingual tablets, microcapsules, etc. Depending on the severity of the symptoms, the age of the subject, sex, weight and sensitivity; duration and administration intervals; properties, administration and type of pharmaceutical preparation; type of active ingredient, etc., the daily dose is not subject to limitation. For use in the treatment of sex hormone-dependent cancers, mentioned above (eg, prosthetic cancer, uterine cancer, breast cancer, pituitary tumor), prostatic hypertrophy, hysteromycin, endometriosis, precocious puberty, etc. The daily dose is usually from about 0.01 to 30 mg, preferably from about 0.02 to 10 mg, and more preferably from 0.1 to 10 mg, per kg of weight of 1 mammal, usually in 1 to 4 divided doses.
The above doses are applicable to the use of the compound of the present invention in the field of raising animals or fish. The daily dose is around 0.01 to 30 mg. Preferably from about 0.1 to 10 mg, per kg of body weight treated, usually in 1 to 3 divided doses.
In the pharmaceutical composition of the present invention, the amount of compound (I) is from about 0.01 to 100% by weight or little more or less, of the total weight of the composition. Pharmaceutically acceptable carriers are various organic and inorganic substances commonly used as pharmaceutical materials, including excipients, lubricants, binders and disintegrators for solid preparations, and solvents, dissolving aids, suspending agents, isotonizing agents, buffers and soothing agents for preparations. liquid. Other pharmaceutical additives, such as preservatives, antioxidants, coloring agents and sweetening agents, may be used, when necessary.
Preferred excipients include, for example, lactose, sucrose, D-mannitol, starch, crystalline cellulose and light salicylic anhydride. Preferred lubricants include, for example, magnesium stearate, calcium stearate, talc and colloidal silica. Preferred binders include, for example, crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and polyvinylpyrrolidone. Preferred disintegrants include, for example, starch, carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium and carboxymethyl sodium starch. Preferred solvents include, for example, water for injection, alcohol, propylene glycol, magrogol, sesame oil and corn oil. Preferred dissolution aids include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethylamine, sodium carbonate and sodium citrate. Preferred suspending agents include, for example, surfers, such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride and glycerol monostearic; and hydrophilic polymers, such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose. Isotonizing agents include, for example, sodium chloride glycerol and D-mannitol. Preferred buffers include, for example, buffer solutions of phosphates, acetates, carbonates, citrates, etc. Preferred soothing agents include, for example, benzyl alcohol. Preferred preservatives include, for example, paraoxybenzoic acid, esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and ascorbic acid. Preferred antioxidants include, for example, sulfites and ascorbic acid.
By the addition of suspending agents, dissolution aids, stabilizers, ISOTONIZING agents, preservatives, etc., the compound of the present invention can be prepared as an intravenous, subcutaneous or intramuscular injection, by a commonly known method. In such cases, the compound of the present invention can be dehydrated by freezing when necessary, by a commonly known method. In administration to humans, for example, the compound of the present invention can be administered safely, orally or non-orally, such as a pharmaceutical composition prepared by mixing with a pharmacologically acceptable carrier, excipient or diluent, selected as appropriate.
Such pharmaceutical compositions include oral preparations (e.g., powders, granules, capsules, tablets), injections, drop infusions, external preparations (e.g., nasal preparations, transdermal preparations) and suppositories (e.g., rectal suppositories, vaginal suppositories). .
These preparations can be produced by methods commonly known in the common use of pharmaceutical manufacturing processes.
An injection can be produced by, for example, the preparation of the compound of the present invention, as an aqueous injection together with a dispersing agent (for example, Tween 80, produced by Atlas Powder Company, USA HCO 60, produced by Nikko Chemicals Co., Ltd prolyethylene glycol, carboxymethyl cellulose, sodium alginate), a preservative (e.g., methyl paraben, propyl paraben, benzyl alcohol), an isotonizing agent (e.g., sodium chloride, mannitol, sorbitol, glucose) and other additives, or as an oily injection in solution, suspension or emulsion in a vegetable oil such as olive oil, sesame oil, cottonseed oil or corn oil, propylene glycol or the like.
An oral preparation can be produced by a method commonly known after the addition of an excipient (e.g., lactose, sucrose, starch), a disintegrator (e.g., starch, calcium carbonate), a binder (e.g., starch, gum arabic, carboxymethyl cellulose), polyvinylpyrrolidine, hydroxypropyl cellulose), a lubricant (eg, talc, magnesium stearate, polyethylene glycol 6000) and other additives, and where it is necessary to coat the appearance of the product for the purpose of masking the taste, enteric or sustained release solution by a commonly known method. The coating agents for this purpose include, for example, hydroxypropylmethyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropylcellulose, polyoxyethylene glycol, Tween 80, Prulonic F68, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, hydroxymethyl cellulose acetate succinate, Eudragit (produced by Rohm Company, Germany; methylacrylic acid / acrylic acid copolymer) and dyes (for example, iron oxide, titanium dioxide). For an enteric preparation, an intermediate phase between the enteric phase and the phase containing the drug can be provided, for the purpose of separating the two phases by a commonly known method.
An external preparation can be produced by the composition of the compound of the present invention as a solid, semi-solid or liquid composition, by a commonly known method Such a solid composition is produced by, for example, spraying the compound of the present invention. invention such as or in a mixture with an excipient (for example, glycol, mannitol, starch, microcrystalline cellulose), a thickening agent (for example, natural gum, cellulose derivative, acrylic acid polymer) and other additives. produced by the preparation of the compound of the present invention as an oily or aqueous suspension in almost the same manner as with injection The semi-solid composition is preferably an aqueous or oily gel, or an ointment. pH 8 for example, carbonic acid, phosphoric acid, citric acid, hydrochloric acid, hydroxide sodium), preservatives, (for example, esters of para-oxybenzoic acid, chlorobutanol, benzalkonium chloride) and other additives.
A suppository is produced by the preparation of the compound of the present invention as an oily or aqueous, solid, semi-solid, or liquid composition, by a commonly known method. Useful oily bases for such compositions include glycerides or higher fatty acids (eg cocoa butter, uitepols, produced by Dinamite Nobel Company, Germany), moderate fatty acids (eg, MIGLYOL, produced by Dinamite Nobel Company, Germany), and vegetable oils (for example, sesame oil, soybean oil, cottonseed oil).
Aqueous bases include, for example, polyethylene glycols and propylene glycol. Bases for aqueous gels include, for example, natural gums, cellulose derivatives, vinyl polymers and acrylic acid polymers.
BEST MODE FOR CARRYING OUT THE INVENTION The present invention is hereinafter described in more detail by means of, but not limited to, the following reference examples, examples, preparation examples and experimental examples.
1 H-NMR spectra were determined with tetramethylsilylamine as the internal standard, using the GEMINI 200 (200 MHz) spectrometer (produced by Varian, Ltd.) the LAMBDA 300 (300 MHz) spectrometer (produced by JEOL, Ltd) or the Bruker spectrometer AM500 (500 MHz) (produced by Bruker): all values of d are shown in ppm. Unless specifically indicated otherwise, "%" is by weight. The yield is indicated in% mol / mol.
The symbols used here have the following definitions: s: singlet d: doublet t: triplet dt: doublet triplet m: multiplet br: broad The term "at room temperature" indicates the range of around 15 to 25 ° C, but not is built as strictly limiting.
EXAMPLES Reference Example 1 Production of 2-amino-5-phenylthiophene-3-carboxylic acid ethyl ester To a mixture of ethyl cyanoacetate (6.1 g, 50 mmol), sulfur (1.61 g, 50 mmol), triethylamine (3.5 mL) , 25 mmol), and dimethylformamide (10 mL), phenylacetaldehyde (50% solution in diethyl phthalate, 12.05 g, 50 mmol) was added dropwise with stirring at 45 ° C for 20 minutes. After stirring at 45 ° C for 9 hours, the reaction mixture was concentrated and the residue obtained was extracted with ethyl acetate and dried (MgSO 4), the solvent was distilled under reduced pressure. The residue was chromatographed on silica gel and recrystallized from ether-hexane to give pale yellow tubular crystals (5.55 g, 45%). mp 124.5-125.5 ° c (lit., 123-124 ° C). Elemental analysis for C? 3H? 3N02S C (%) H (%) N (%) Calculated: 63.13; 5.30; 5.66 Found: 62.99; 5.05; 5.63 XH-NMR (300MHz, CDCl3) 6: 1.37 (3H, t, J = 7.1Hz), 4.30 (2H, d, J = 7.1Hz), 5.97 (2H, br), 7.17-7.46 (6H, m) . IR (KBr): 3448, 3320, 1667, 1590, 1549 cm -i
Reference Example 2 Production of 2-amino-4-methyl-5- (4-methoxyphenyl) thiophene-3-carboxylic acid ethyl ester A mixture of 4-methoxyphenylacetone (16.5 g, 0.10 mol), ethyl cyanoacetate (12.2 g) , 0.10 mol), ammonium acetate (1.55 g, 20 mmol), acetic acid (4.6 mL, 80 mmol) and benzene (20 mL) was heated for 24 hours, while the water that was produced was removed using a Dean apparatus. -Stark. After cooling, the reaction mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane and aqueous sodium bicarbonate. Then, the organic layer was washed with saline and dried (MgSO 4), the solvent was distilled under reduced pressure. To a solution in methanol (30 mL) of the obtained residue, sulfur was added
(3.21 g, 0.10 mol) and diethylane (10.44 mL, 10.10 mol), followed by stirring at 50 to 60 ° C for 2 hours, successively the reaction mixture was concentrated. The residue obtained was extracted with ethyl acetate, washed with saline and dried (MgSO), the solvent was distilled under reduced pressure. The residue was chromatographed on silica gel and recrystallized from ether-hexane to give light yellow tubular crystals (11.5 g, 40%). mp 79-80 ° C. Elemental analysis for C15H17NO3S C (%) H (%) N (%) S (%) Calculated: 61.83; 5.88; 4.81; 11.01 Found; 6X81; 5.75; 4.74; 10.82 XH-NMR (200MHz, CDCI3) d: 1.37 (3H, t, J = 7.1Hz), 2.28 (3H, s), 3.83 (3H, s), 4.31 (2H, q, J = 7.1Hz), 6.05 (2H, brs), 6.91 (2H, d, J = 8.8Hz), 7.27 (2H, d, J = 8.8Hz). IR (KBr): 3426, 3328, 1651, 1586, 1550, 1505, 1485 can "1. FAB-MS m / z: 291 (M +).
Reference Example 3 Using some acetone derivatives in place of 4-methoxyphenylacetone, the following compound was obtained in the same manner as in Reference Example 2.
Yield: 40% mp 64-65 ° C.
Reference Example 4 Production of [3-ethoxycarbonyl-5- (4-methoxyphenyl) -4-methylthiophen-2-yl] aminomethylene-malonic acid diethyl ester To the compound obtained in Reference Example 2 (10 g, 34.3 mmol), diethyl ether of ethoxymethylenemalonic acid (7.45 g, 34.5 mmol) was added, followed by stirring at 120 ° C for 2 hours. After the reaction mixture was cooled, the precipitated crystals were collected by filtration via ether addition, washed again with ether, and dried over phosphorus pentaoxide, under reduced pressure, to give yellow crystals (14.2 g, 90 %). mp 122-123 ° C. -? - NMR (200MHz, CDC13) d: 1.32 (3H, t, J = 7.1Hz), 1.38 (3H, t, J = 7.2Hz), 1.41 (3H, t, J = 7.2Hz), 2.34 (3H , s), 3.85 (3H, s), 4.25 (2H, q, J = 7.1Hz), 4.38 (2H, q, J = 7.2Hz), 4.45 (2H, q, J = 7.2Hz), 6.95 (2H , d, J = 8.8Hz), 7.31 (2H, d, J = 8.8Hz), 8.22 (1H, d, J = 13.4Hz), 12.74 (1H, d, J = 13.1Hz). IR (KBr): 2984, 1720, 1707, 1688, 1653, 1599, 1518, 1499 c '-1
Reference Example 5 Using the compound obtained in Reference Example 3 as starting material, the following compound was obtained in the same manner as in Reference Example 4.
Yield 92% Mp 108-109 ° C.
Reference Example 6 Production of 3-carboxy-5- [(4-methoxyphenyl) -4-methylthiophen-2-yl] aminomethylenemalonic acid diethyl ester To a solution in dioxane (20 mL) of the compound obtained in Reference Example 4 (7.0 g, 15.2 mmol), a solution of potassium hydroxide (5.0 g, 75.7 mmol) in ethanol (30 mL) was added with stirring at the temperature between 60 to 70 ° C. After stirring at this temperature for 1 hr, the reaction mixture was allowed to stand at room temperature for 1 hour. To the mixture was added 2 N hydrochloric acid (40 mL, 80 mmol) with ice cooling, the reaction mixture was concentrated under reduced pressure. The yellow precipitate was collected by filtration, washed with cold water-ethanol, and dried over phosphorus pentaoxide under reduced pressure, to give yellow powders (6.1 g, 93%).
mp 184-187 ° C. - H-NMR (200MHz, DMSO-d6) d: 1.24 (3H, t, J-7.1Hz), 1.28 (3H, t, J = 7.2Hz), 2.30 (3H, s), 3.80 (3H, s ), 4.15 (2H, q,
J = 7.1Hz), 4.24 (2H, q, J = 7.2Hz), 7.03 (2H, d, J = 8.7Hz), 7.37
< 2H, d7 J = 8.7Hz), 8.08 (1H, d, J = 13.6Hz), 12.41 (1H, d,
J = 13.6Hz). IR (KBr): 3422, 2980, 1719, 1653, 1607, 1551, 1512 c "1.
Reference Example 7 Using the compound obtained in the Example of
Reference 5 as the starting material, the following compound was obtained in the same manner as in Reference Example 6.
Rendimi in t o: 98% mp 187-190 ° C.
Reference Example 8 Production of 4-hydroxy-2- (4-α-ethoxyphenyl) -3-methylthioeno [2, 3-b] pyridine-5-carboxylic acid ethyl ester Small portions of the compound obtained in Reference Example 6 ( 6.0 g, 13.8 mmol) were added with stirring at 120 ° C to the polyphosphoric acid ester (PPE) (90 mL). After stirring at the same temperature for 30 min, the reaction mixture was poured into ice water, extracted with ethyl acetate. The combined extracts were washed with saline, and dried (MgSO 4), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel, to give yellow powders (3.65 g, 77%) for a sample for elemental analysis, the obtained powders were recrystallized from ethanol to obtain yellow crystals, mp 162-163 ° C. Elemental analysis for Ci8Hi7N04S C (%) H (%) N (%) S (%) Calculated: 62.96; 4.99; 4.08; 9.34 Found: 62.89; 5.04; 4.01; 9.34 - • -H-NMR (200MHz, CDC13) d: 1.47 (3H, t, J = 7.1Hz), 2.63 (3H, s), 4.87 (3H, s), 4.49 (2H, q, J = 7.1Hz ), 6.99 (2H, d, J = 8.8Hz), 7.44 (2H, d, J = 8.8Hz), 8.84 (lH, s) r 12.11 (1H, s). IR (KBr): 3434, 2992, 1692, 1601, 1582, 1535, 1504 cm "1. FAB-MS m / z: 344 (MH +).
Reference Example 9 Using the compound obtained in Reference Example 7 as an initial material, the following compound was obtained in the same manner as in Reference Example 8.
Yield: 60% Mp 155-157 ° C.
Reference Example 10 Production of 4-hydroxy-2- (4-nitrophenyl) -3-methylthieno [2, 3-b] pyridine-5-carboxylic acid ethyl ester To a solution in concentrated sulfuric acid (10 mL) of the compound obtained in Reference Example 9
(3.76 g, 12.0 mmol) was added dropwise a solution of sodium nitrate (1.27 g, 15.0 mmol) in concentrated sulfuric acid (5 mL) with ice cooling. After stirring at this temperature for 30 minutes, the reaction mixture was poured into ice water and extracted with chloroform. The combined extracts were washed with saline, and dried (MgSO4), the solvent was distilled under reduced pressure. The obtained residue was subjected to chromatography on silica gel, to obtain yellow powders, which were recrystallized from ethanol, to obtain yellow crystals (1.75 g, 41%) mp 260-261 ° C. Elemental analysis for Ci7Hi4N205S C (%) H (%) N (%) Calculated: 56.98; 3.94; 7.82 Found: 56.66; 3.91; 7.86 -? - NMR {200MHz, CDC13) d: 1.49 (3H, t, J = 7.1Hz), 2.70 (3H, s), 4.51 (2H, q, J = 7.1Hz), 7.70 (2H, d, J = 8.8Hz), 8.3 (2H, d, J = 8.8Hz), 8.89 (1H, s), 12.27 (1H, s). IR (KBr): 3002, 1692, 1605, 1514, 1350, 1290 cm "1. FAB-MS m / z: 358 (MH +).
Reference Example 11 Production of 4,7-dihydro-7- (2-methoxybenzyl) -2- (4-methoxyphenyl) -3-methyl-4-oxothieno [2, 3-b] pyridin-5-ethyl ester carboxylic acid To a suspension of sodium hydride (60% dispersion in oil;, 123 mg, 3.08 mmol) in dimethylformamide (3 mL) was added a solution of the compound obtained in the
Reference Example 8 (1.0 g, 2.91 mol) in dimethylformamide
(20 mL) under a stream of nitrogen with ice cooling. After stirring at this temperature for 30 minutes, a solution of 2-methoxybenzyl chloride (0.92 g, 5.87 mmol) in dimethylformamide (3 mL) was added dropwise to the mixture. After stirring at room temperature for 23 hours and at 70 ° C for 2 hours, the reaction mixture was concentrated, and then the obtained residue was partitioned between ethyl acetate and an aqueous solution of ammonium chloride. The aqueous layer was extracted with ethyl acetate. The combined extracts were washed with saline, and dried (MgSO 4), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel to give yellow amorphous powders (0.95 g, 70%). For a sample for elemental analysis, the obtained powders were recrystallized from dichloromethane-ether to obtain yellow prismatic crystals. mp 165-167 ° C. Elemental analysis for: C26H25NO5S 0.5H2O C (%) H (%) N (%) Calculated: 66.08; 5.55; 2.96 Found: 66.33; 5.44; 2.74 Trl-NMR (200MHz, CDCI3) d: 1.41 (3H, t, J = 7.1Hz), 2.65 (3H, s), 3.85 (3H, s), 3.86, (3H, s), 4.39 (2H, q , J = 7.1Hz), 5.16 (2H, s), 6.92-7.00 (4H,), 7.21-7.41 (4H, m), 8.41 (1H, s). GO . { KBr): 2980, 1727, 1684, 1609, 1590, 1497, 1464 c "1.
Reference Example 12 The following compound was produced by the same method as described in Reference Example 11, using benzyl 2,6-difluorochloride in place of 2-methoxybenzyl chloride with the compound obtained in Reference Example 10 as the initial material.
Yield 81% mp 215-217 ° C.
Reference Example 13 Production of 3-bromoacetyl-4,7-dihydro-7- (2-methoxybenzyl) -2- (4-methoxyphenyl) -4-oxothieno [2, 3-b] pyridin-5-ethyl ester carboxylic A mixture of the compound obtained in Reference Example 11 (0.35 g, 0.755 mol), N-bromosuccinimide (0.135 g, 0.758 mmol), a, a'-azobisisobutyronitrile (13 mg, 0.079 mmol), and carbon tetrachloride ( 5 mL) was heated and refluxed for 2 hours. After cooling, the insoluble substances were filtered, then the filtrate was diluted with chloroform. After, the organic layers were washed with saline and dried (MgSO 4), the solvent was distilled under reduced pressure. The residue obtained was recrystallized from ethyl acetate to obtain colorless needles (0.272 g, 66%). mp 200-201 ° C. Elemental analysis for CaeH ^ NOsSBr C (%) H (%) N (%) Calculated: 57.57; 4.46; 2.58 Found: 57.75; 4.31; 2.31 1H-HMR (200MHz, CDC13) d: 1.40 (3H, t, J = 7.1Hz), 3.86 (6H, s), 4.40. { 2H, q, J = 7.1Hz), 5.05 (2H, s), 5.16 (2H, s), 6.92-7.04 (4H,), 7.23-7.28 (lH,), 7.34-7.43 (1H, m), 7.57 . { 2H, d, J = 8.9Hz), 8.46 (1H, s). IR (KBr): 2980, 1725, 1607, 1588, 1497 cm "1.
Reference Example 14 Using the compounds obtained in the Examples of
Reference 12, 22 and 27 as initial materials, respectively, the following compounds were obtained
(Reference Examples 14-1 to 14-3), in the same manner as in Reference Example 13.
Reference Example 14-1: Rendimi ent o: 81% Pí 200-202 ° c.
Reference Example 14-2:
Yield: 80% Amorphous
Reference Example 14-3
Yield: 79% Mw 189-192 ° C.
Reference Example 15 Production of 3- ± ethyl acid ester > Cilaminomethyl-4, 7-dihydro-7-. { 2-methoxybenzyl) -2- (4-methoxyphenyl) -4-oxothieno [2,3-b] pyridine-5-carboxylic acid To a solution of the compound obtained in Reference Example 13 (0.245 g, 0.452 mmol) in dimethylformamide ( 5 mL) triethylamine (0.10 mL) was added., 0.717 mmol) and benzylamine (80 μl, 0.732 mmol) with ice cooling. After stirring at room temperature for 1.5 hours, the reaction mixture was concentrated, and then the residue obtained was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The aqueous layer was extracted with ethyl acetate. The combined organic extracts were dried (MgSO), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel to obtain a colorless oil (0.135 g, 53%). To a solution of this oil in ethanol (4 mL) was added ethanolic hydrochloric acid ION (0.2 mL) with ice cooling, followed by stirring at this temperature for 10 minutes. The reaction mixture was concentrated, and then, the obtained residue was crystallized from ethyl acetate-ether to obtain the hydrochloride (0.113 g) as white crystals. pf [Hydrochloride] 118-119 ° C. Elemental analysis for C33H32N205S HCl 0.9H20 C (%) H (%) N (%) Calculated: 63.79; 5.64; 4.51 Found: 64.03; 5.44; 4.51 - H-NMR. { 300MHz, CDC13) [Free amine] d: 1.40. { 3H, t, J = 7.1Hz), 2.05 (1H, br), 3.81 (3H, s), 3.86 (3H, s), 3.87 (2H, s), 3.94 (2H, s), 4.40 (2H, q , J = 7.1Hz), 5.18 (2H, s), 6.80 (2H, d, J = 8.8Hz), 6.91-6.99 (2H, m), 7.20-7.42 (9H, m), 8.45 (1H, s) . IR (KBr) [Hydrochloride]: 3422.2938, 1719.1605, 1560.1545,
Reference Example 16 Production of 4-methyl-2- [(4-methyl-3-oxo-l-penten-1-yl) amino] -5-phenylthiophene-3-carboxylic acid ethyl ester The compound obtained in Example of Reference 3 (10 g), l-methoxy-4-methyl-l-penten-3-one with 85% content (6.9 g), p-toluenesulfonic acid monohydrate (0.219 g), and toluene (100 mL) they were mixed and stirred at room temperature for 2.5 hours. Then, the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous sodium hydrogen carbonate solution, the aqueous layer was extracted with ethyl acetate. The combined extracts were washed with saturated saline, the organic layers were dried over anhydrous magnesium sulfate. The residue was crystallized via the addition of a seed crystal, after which it was triturated with hexane, collected by filtration, and washed, to give the title compound (12.64 g, 92%), mp 104-108 °. C.
Reference Example 17 Production of 4,7-dihydro-7- (2-methoxybenzyl) -2- (4-methoxyphenyl) -3-methyl-4-oxothieno [2,3-b] pyridine-N-benzylpiperazinyl-5- carboxamide A 1-benzylpiperazine (0.77 g, 4.37 mmol) was added dropwise a solution of diisobutyl aluminum hydride
(DIBAL) in toluene (1.5 N, 2.9 mL, 4.37 mmol) with ice cooling. After the addition was complete, the solution was allowed to warm to room temperature and was stirred for another 0.5 hour.To this solution was added a solution of the compound obtained in Reference Example 11 (0.50 g, 1.08 mmol) in toluene (5 mL) at room temperature, then the mixture was stirred again at room temperature for 15 hours, methylene chloride 830 mL was added) After washing with water, the solution was dried over sodium sulfate, and then the solvent was concentrated under reduced pressure to give a solid (1.03 g), which was recrystallized from methylene chloride-n-hexane, to give the title compound. {0.48 g, 78%) .pf 233-235 ° C Elemental analysis for C35H35N3O4S 1 / 2H20 C {%) H (%) N (%) S (%) Calculated: 69.75; 6.02: 6.97; 5.32. Found: 69.88; 6.06: 6.98; 5.39 .1H-NMR (300MHz, CDCI3) d: 2.45-2.55 (4H, m), 2.63 (3H, s), 3.43-3.45 {2H, m), 3.55 (2H, s), 3.73-3.82 (2H ,), 3.84 (6 H, s), 5.11 (2H, s), 6.89-6.98 (4H, m), 7.21-7.40 (9H, m), 7.79 (1H, s).
Reference Example 18 Using the compound obtained in Reference Example 12 as starting material and N, 0-dimethylhydroxy, instead of 1-benzylpiperazine, the following compound was obtained in the same manner as in Reference Example 17.
Yield: 80% Pf 223-224 ° C.
Reference Example 19 Production of 4-hydroxy-5-isobutyryl-3-methyl-2-phenyltiene [2, 3-b] pyridine The compound obtained in Reference Example 16 (50 g) and diphenylether (500 mL) was they mixed, and then, this mixture was heated and refluxed for 4 hours, while the methanol that was produced with the progress of the reaction was distilled. After cooling, the diphenylether was distilled under reduced pressure, and then the precipitated crude crystals were washed with n-hexane to give the title compound. { 35.1 g, 81%). Mp 114-117 ° C.
Reference Example 20 Using the compound obtained in Reference Example 14-1 as starting material and N-methoxybenzylamine instead of benzylamine, the following compounds were obtained (Reference Examples 20-1 to 20-3), in the same manner as in Reference Example 15.
Reference Example 20-1
Ren i mi ent o: 83% Pf 140-144 ° C.
Reference Example 20-2;
Yield 91% Mp 145-147 ° C.
Reference Example 20-3: Yield: 78% mp 175-177 ° C.
Reference Example 21 Using the compounds obtained in Reference Example 20 as the starting materials (Reference Examples 21-1 to 21-3), were obtained in the same manner as in Reference Example 28.
Reference Example 21-1:
Yield: 79% mp 158-160 ° C.
Reference Example 21-2:
Yield: 96% mp 195-196 ° C.
Reference Example 21-3:
Yield :: 71% mp 144-146 ° C.
Reference Example 22 Production of 7- (2,6-difluorobenzyl) -4,7-dihydro-5-isobutyl-3-methyl-4-oxo-2-phenyl-thieno [2,3-b] pyridine The compound obtained in Reference Example 19 (35 g), potassium carbonate (18.6 g), and N, N-dimethylformamide (280 mL), were mixed, and then 2,6-difluorobenzyl bromide (27.9 g) was added, followed by by stirring at room temperature for 4 hours. Water was added dropwise to the reaction mixture. { 560 mL), followed by stirring for 30 minutes, and then the mixture was stirred for 1 hour with ice cooling. The crude crystals were collected by filtration, washed with water, and dried, successively suspended in a 1: 1 solvent mixture. { 250 mL) of ethyl acetate or diisopropyl ether and stirred at 25 to 40 ° C for 1 hour, then stirred with ice cooling for 1 hour, the residual crystals were collected by filtration and washed with the solvent mixture. from above (125 mL) to give the title compound (44.6 g, 92%). mp 205-207 ° C.
Reference Example 23 Using the compounds obtained in Reference Example 14-2 and Reference Example 24 as the starting materials and N-methylbenzylamine, instead of benzylamine, the following compounds were obtained (Reference Examples 23-1 to 23 -2), in the same manner as in Reference Example 15.
Reference Example 23-1:
Yield: 83% mp 197-199 ° C.
Reference Example 23-2
Retreatment: 66% mp 151-152 ° C.
Reference Example 24 * Production of 3-bromomethyl-7- (2,6-difluorobenzyl) -4,7-dihydro-5-isobutyryl-2- (4-nitrophenyl) -4-oxothieno [2,3-b] pyridine After the compound obtained in the Example of
Reference 14-3 (1 g), dissolved in methanesulfonic acid
(5 mL) with a cooling of 10 to 12 ° C, a solution of sodium nitrate (0.165 g) in methanesulfonic acid (2.5 mL) was added dropwise to this mixture. After being stirred for 2 hours, the mixture was poured into cold water, and then the crystalline precipitate was collected by filtration, washed with water and diisopropyl ether, and dried to give a crude product (1.04 g), which it was then triturated with ethyl acetate (15 mL), then cooled with ice, filtered, and washed with cold ethyl acetate to give the title compound (0.647 g, 59%). Mp 202 to 204 ° C (recrystallized from methanol).
Reference Example 25 Production of 4,7-dihydro-7- (2,6-difluorobenzyl) -2- (4-nitrophenyl) -3- (N-benzyl-N-methylaminomethyl) -4-oxothiene [2, 3- b} j > iridine-5- (N-isopropyl) carboxamide To a solution of isopropylamine (0.296 g, 5 mmol) in anhydrous methylene chloride (5 mL) was added dropwise a solution of trimethylaluminum in hexane (15%, 2.41 mL, 5.0 mmol) at 0 ° C. After the addition was complete, the solution was allowed to warm to room temperature and further stirred for 1 hr. To this solution was added a solution of the compound obtained in Reference Example 20-2 (0.12 g, 0.25 mmol) in anhydrous methylene chloride (3 mL) with ice cooling (0 ° C) for 30 minutes. Then, the mixture was stirred at room temperature for another hour, chloroform was added, followed by washing with water. The combined organic layers were dried with sodium sulfate, and then the solvent was concentrated under reduced pressure, to give a solid, which was recrystallized from chloroformyl acetate-ethyl ether, to give colorless crystals (0.96 g, 70% ). mp 200-202 ° C. 1H-NMR (500MHz, CDC13) [Free amine] d: 1.30 (6H, d, J = 6.7Hz), 2.15 (3H, s), 3.66 (2H, s), 4.18 (2H, s), 4.18-4.31 (1H, m), 5.32 (2H, s), 7.00 (2H, t, J = 7.26Hz), 7.13-7.25 (5H, m), 7.42 (1H, t, J = 7.3Hz), 8.02 (2H, d, J = 8.9Hz), 8.26 (2H, d, J = 8 .9Hz), 8.73 (1H, s), 10.02 (1H, d, J = 9.1Hz). IR (KBr): 2974, 1661, 1597, 1547, 1497, 1346, 1212, 1035 cm "1 FAB-Mass m / z 617 (MH) +.
Reference Example 26 Using the compound obtained in Reference Example 20-2 as an initial material and N, 0-dimethylhydroxyamine, the following compound was obtained, in the same manner as in Reference Example 25.
Yield: 96% mp 100-102 ° C.
Reference Example 27 Production of 4,7-dihydro-7- (2,6-difluorobenzyl) -2- (4-nitrophenyl) -5-benzyl-3-methyl-4-oxothieno [2,3-b] pyridine The The compound obtained in Reference Example 18 (3.93 g, 7.87 mmol) was dissolved in anhydrous tetrahydrofuran (THF) with slight heating. While this solution was maintained at 0 ° C, a solution of phenylmagnesium bromide in THF (1M, 15.7 mL, 15.7 mmol) was added dropwise to the mixture over 10 minutes. After the addition was complete, the solution was stirred for an additional 1 hour. The reaction mixture was partitioned between ethyl acetate (200 mL) and water. { 50 L), and then the aqueous layer was extracted again with ethyl acetate. The combined organic layers were dried with magnesium sulfate, the solvent was concentrated under reduced pressure, to give a residue, which was chromatographed on silica gel, to give yellow crystals (3.00 g, 74%), which they were recrystallized from ethyl acetate-hexane, to give yellow crystals. mp 114-116 ° C. Elemental analysis for C28H? 8N204SF2 0.7H20 C (%) H (%) N (%) Calculated: 63.56; 3.70; 5.29 Found: 63.83; 3.95; 5.08 H-NMR (500MHz, CDC13) d: 2.68 (3H, s), 5.30 (2H, s), 7.02 (2H, t, J = 8.lHz), 7.43 (3H, t, J = 7.2Hz), 7.52-7.63 (3H, m), 7.86. { 2H, d, J = 7.5Hz), 7.99 (1H, s), 8.30 (2H, d, J = 8.7Hz). IR (KBr): 3422, 3068, 1665, 1615, 1491, 1473, 1346, 853 cm "1. FAB-Mass m / z 517 (MH) +.
Reference Example 28 Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-7- (2,6-difluorobenzyl) -2- (4-aminophenyl) -5-benzoyl-4-oxothiene [ 2, 3-b] pyridine To a mixture of the compound obtained in Reference Example 23-1 (0.30 g, 0.47 mmol), in ethyl alcohol
(6 mL), water (2 mL) was added, and then a drop of concentrated hydrochloric acid was added to give a uniform solution. - To this solution were added iron powder.
(0.105 g, 2.0 mmol) and concentrated hydrochloric acid (0.39 mL, 4.7 mmol) carefully. After the addition was complete, the mixture was stirred at room temperature for 5 hours and filtered through Celite. A small amount of aqueous ammonia was added, and then, the reaction filtrate was concentrated under reduced pressure. The obtained residue was poured into ice water, neutralized with sodium bicarbonate, and extracted with ethyl acetate. After, the combined organic layers were washed with saline, and dried (MgSO4), the solvent was distilled off under reduced pressure. The residue obtained was subjected to chromatography on silica gel and recrystallized from isopropyl ether, to give yellow needles (0.24 g, 84%). mp 126-128 ° C. Elemental analysis for C36H29N302SF2 1 / 2H20 C (%) H (%) N (%) Calculated: 68.93; 5.04; 6.70 Found: 68.71; 5.18; 6.62 - H-EuMR. { 300MHz, CDC13) d: 2.13 (3H, s), 3.65 (2H, s), 3.87 (2H, br s), 4.14 (2H, s), 5.28 (2H, s), 6.74 (2H, d, J = 8.7Hz), 7.00. { 2H, t, J = 7.8Hz), 7.16-7.24 (5H, m), 7.36-7.46 (3H, m), 7.53 (1H, t, J = 7.2Hz), 7.62 (2H, d, J = 8.4Hz ), 7.89 (2H, d, J = 7.2Hz), 7.94 (1H, s). IR (KBr): 3358, 1607, 1495, 1473, 1035 cm "1. FAB-Mass m / z 606 (MH) +.
Reference Example 29 Production of 2- (4-aminophenyl) -7-. { 2,6-difluorobenzyl) -4,7-dihydro-5-isobutyryl-3- (N-benzyl-N-methylaminomethyl) -4-oxothieno [2,3-b] pyridine
To a solution of the compound obtained in Reference Example 23-2 (0.25 g, 0.415 mmol) in methanol (5 mL) were added dropwise (0.093 g, 1.66 mmol) and concentrated hydrochloric acid. { 0.8 mL) with ice cooling. After the addition was complete, the mixture was stirred at room temperature for 1 hour and filtered through Ceuta. A small amount of aqueous sodium hydrogen carbonate solution was added, followed by extraction with methylene chloride (30 mL x 3). The combined extracts were washed with saline, and dried (MgSO4), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel to give light yellow amorphous powders (0.203 g, 86%).
^ -NMR (300MHz, CDC13) d: 1.18 (6H, d), 2.11 (3H, s), 3.65 (2H, s),
3. 85 { 2H, br s), 4.17 (2H, s), 4.18 (1H, m), 5.25 (2H, s),
6. 73 (2H, d), 6.95 (2H, t), 7.10-7.26 (5H,), 7.42 (1H, m), 7.58. { 2H, d), 8.27. { 1H, s).
Reference Example 30 Production of 5-benzoyl-7- (2,6-difluorobenzyl) -4,7-dihydro-3- (N-benzyl-N-methylaminomethyl) -2- (4-propionylaminophenyl) -4-oxothiene [ 2, 3-b] pyridine The compound obtained in Reference Example 28 (0.14 g, 0.23 mol) was dissolved in anhydrous methylene chloride (2 mL), and then triethylamine (0.038 L) was added to the mixture with cooling of ice (0 ° C). After this solution was stirred for a moment, propionyl chloride (0.021 mL, 0.243 mmol) was added to the mixture, after the addition was complete, the solution was further stirred with ice cooling (0 ° C) for 40 minutes. minutes The reaction mixture was partitioned between methylene chloride (25 mL) and barely covered with a layer of water (10 mL). The aqueous layer was extracted again with methylene chloride (25 mL). The combined organic layers were washed with saline, and dried (MgSO 4), the solvent was distilled under reduced pressure. The solid obtained was recrystallized from ethyl acetate-isopropyl ether, to give yellow needles (0.10 g, 65%). mp 226-228 ° C. Elemental analysis for C39H33N303SF2 0.7H20 C (%) H (%) N (%) Calculated: 69.46; 5.14; 6.23 Found: 69.60; 5.18; 6.04
The compound thus obtained was dissolved in ethyl acetate, and then a saturated solution of hydrogen chloride (HCl) in ether was added, in an amount equal to slightly in excess, and then the crystalline precipitate was recrystallized from ether isopropyl, to give light yellow needles (0.095 g, 61%). mp 218-220 ° C. Elemental analysis for C39H33N3O3SF2 HCl 3.5H20 C (%) H (%) N (%) Calculated: 61.53; 5.43; 5.52 Found: 61.83; 5.33; 5.30 1H-HMR (300MHz, DMSO-d6) d: 1.11 (3H, t, J = 7.2Hz), 1.93 (3H, s), 2.35 (2H, q, J = 7.5Hz), 3.44 (2H, s) , 4.00 (2H, s), 5.62 (2H, s), 7.11-7.25 (6H, m), 7.43-7.72 (10H, m), 7.79. { 2H, d, J = 7.5Hz), 8.40 (1H, s), 10.03 (1H, s). IR (KBr): 3422, 3068, 1603, 1502, 1473, 1035 c "1. FAB-Mass m / z 662 (MH) +.
Reference Example 31 The following compounds (Reference Example 31-1 to 31-10) were produced by the same method as that described in Reference Example 30, using various chlorides of acid, isocyanates, and esters of chlorocarbonic acid, in place of propionyl chloride, and, also using the amines shown in Example 16 and carbonyldiimidazole, with the compounds obtained in Reference Examples 28 and 29 as the starting materials. The following compounds (Reference Examples 31-11 to 31-16) can be produced in the same manner.
Reference Example 31-1-1: Yield: 68% Mp 238-240 ° C.
Reference Example 31-1-2:
mp 230-232 ° C.
Reference Example 31-2-1:
yield: 64% mp 201-204 ° C.
Reference Example 31-2-2:
Reference Example 31-3-1:
Yield: 55% Mw 207-210 ° C.
Reference Example 31-3-2:
mp 222-226 ° C,
Reference Example 31-4:
Yield: 49% mp 185-187 ° C
Reference Example 31-5:
Yield: 79% Mp 216-218 ° C.
Reference Example 31-6;
Yield: 73% Mp 180-183 ° C.
Reference Example 31-7
Yield: 65% Mw 245-247 ° C.
Reference Example 31-8:
Performance 65%
Reference Example 31-9:
Rendimi at t o: 70% Mw 232-234 ° C.
Reference Example 31-10:
Yield: 73% Mw 192-197 ° C.
Reference Example 31-11;
Reference Example 31-12: Reference Example 31-13: Reference Example 31-14
Reference Example 31-15: Reference Example 31-16:
Reference Example 32 Production of 3- (-N-benzyl-N-methylaminomethyl) -4,7-dihydro-7- (2,6-difluorobenzyl) -2- (4-nitrophenyl) -5-benzoyl-4-oxothiene [2, 3-b] pyridine The compound obtained in Reference Example 26. { 1.91 g, 3.09 mmol) was dissolved in anhydrous tetrahydrofuran (THF) (30 mL), with heating, and then added to the. drop by drop, a solution of phenylmagnesium bromide in THF (1M, 6.18 mL, 6.2 mmol) with ice cooling (0 ° C) for 10 minutes. After stirring under the conditions of ice cooling for 1 hr, the reaction mixture was partitioned between ethyl acetate (100 mL) and aqueous hydrochloric acid (0.5N, 100 mL), and then, the organic layer was washed again once with saturated saline solution (10 mL). After the organic layer was dried (MgSO), the solvent was distilled under reduced pressure. The obtained residue was subjected to chromatography on silica gel, to give yellow crystals (1.00 g, 51%), which were then recrystallized from isopropyl ether, to give yellow needles. mp 197-199 ° C. Elemental analysis for C36H27N304SF2 0.7H20 C (%) H (%) N (%) Calculated: 66.70; Four . 42; 6.48 Found: 66. 59; Four . 48; 6. 42 1 H-NMR (300MHz, CDCl 3) d: 2.17 (3H, s), 3.61 (2H, s), 4.16 (2H, s), 5.30 (2H, s), 7.03 (2H, t, J; 8.1 Hz), 7.19-7.25. { 5H,), 7.40-7.47 (3H, m), 7.56 (1H, t, J = 7.5Hz), 7.88 (2H, d, J = 6.9Hz), 7.96 (1H, s), 8.10 (2H, d, J = 8.7Hz), 8.28 (2H, d, J = 8.7Hz). IR (KBr): 3430.1663, 1611, 1518, 1473, 1348, 853 c "1. FAB-Mass m / z 636 (MH) +.
Reference Example 33 Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-7- (2,6-difluorobenzyl) -2- (4-isobutyrylaminophenyl) -5- (2-bromoisobutyryl) - 4-Oxothieno [2, 3-b] pyridine The compound obtained in Reference Example 31-10 (0.48 g, 0.75 mmol) was dissolved in dichloromethane (15 mL). To this solution was added dropwise 47% hydrobromic acid 80.35 L, 3.0 mmol) at room temperature for 1 minute, followed by further stirring for 10 minutes. To this reaction mixture was added dropwise bromine (39 μl, 0.75 mmol), followed by further stirring at room temperature for 24 hours. The reaction mixture was partitioned between dichloromethane (30 mL) and aqueous sodium bicarbonate (saturated, 60 mL), and then the organic layers were washed again with saturated saline (100 mL). After the organic layer was dried (MgSO 4) the solvent was distilled under reduced pressure to give brown amorphous crystals (0.53 g).
Reference Example 34 Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-7- (2,6-difluorobenzyl) -2- (4-isobutyrylaminophenyl) -5-methacryloyl-4-oxothiene [ 2, 3-b] pyridine The compound obtained in Reference Example 33. { 0.52 g, 0.72 mmol) was dissolved in dimethylformamide (DMF) (30 mL), and then, to this solution was added potassium acetate (2.0 g, 20 mmol) at room temperature, followed by stirring at 100 ° C for 20 minutes. hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and water (30 mL), and then, the aqueous layer was washed again with ethyl acetate (10 mL). The combined organic layers were washed again with saturated saline (30 mL). After, the organic layer was dried (MgSO), the solvent was distilled under reduced pressure to give a brown oil (0.56 g).
Example 1 Example 1-1: Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- (4-cyclopropanecarbonylaminophenyl) -4 -oxotiene [2, 3-b] pyridine
To a solution of the compound obtained in Reference Example 29 (2.57 g, 4.5 mmol) in dichloromethane (30 mL) were added cyclopropanecarboxylic acid (861 mg, 10 mmol) and diisopropylethylamine (2.59 g, 20 mmol), and then benzotriazole acid -1-yl-oxy triprrolidino phosphonium hexafluorophosphoric acid (PyBop) (5.40 g, 10 mmol), was added to it in a small portion with ice cooling. After stirring at room temperature for 1 day, the reaction mixture was poured into a 0.1 N aqueous solution of potassium hydroxide and extracted with chloroform. The combined extracts were washed with saline, and dried (Na2SO), the solvent was distilled under reduced pressure. The obtained residue was chromatographed on silica gel and recrystallized from ethyl acetate to give white powdered crystals (2.15 g, 79%). 1 H-NMR (300MHz, CDCl 3) d: 0.85-0.90 (2H, m), 1.10-1.15 (2H, m), 1.18 (6H, d), 1.53-1.59. { 1H, m), 2.09 (3H, s), 4.12-4.20 (1H, m), 4.16. { 2H, s), 5.25 (2H, s), 6.99. { 2H, t), 7.10-7.25 (6H, m), 7.35-7.45 (lH, m), 7.61 (2H, d), 7.67 (1H, br s), 7.76. { 2H, d),
8. 27 (1H, s). FAB-Mass m / z 608 (MH) +.
JExample 1-2: Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- (4-cyclopropanecarbonylaminophenyl) -4 hydrochloride -oxotiene [2, 3-b] pyridine
The white powdered crystals obtained in Example 1-1 were dissolved in ethanol, and then, a solution of hydrogen chloride in ethyl ether was added in a small amount in excess, followed by recrystallization from ethanol-ethyl ether. , to give powdered crystals of white color (2.20 g, 72%). mp 254-256 ° C. Elemental analysis for C37H35N303SF2 HCl C. { %) H (%) N (%) Calculated: 65.72; 5.37; 6.21 Found: 65.61; 5.38; 6.25 IR (KBr): 2950, 1673, 1595, 1502, 1473, 1408, 1313, 1183 cm "1.
Example 2 Production of 4,7-dihydro-2- [4- (3-acetoxy-2-methylpropionylamino) phenyl] -7- (2,6-dicluorobenzyl) -3- (N-benzyl-N-methylaminomethyl) -5 -isobutyryl-4-oxothieno [2, 3-b] pyridine
To a solution of the compound obtained in Reference Example 20 (1.14 g, 2.0 mmol) in dichloromethane (30 mL) were added dropwise, triethylamine (500 mg, 5 mmol) and 3-acetoxyisobutyryl chloride (0.5 g, 3 g). mmol) with ice cooling for one minute, followed by further stirring at room temperature for 1 hr. The reaction mixture was partitioned between an aqueous solution of sodium hydrogen carbonate (30 mL) and dichloromethane (30 mL), and then the organic layer was extracted again with dichloromethane (10 mL). The combined extracts were washed with saline, and dried (Na2SO4), the solvent was distilled off under reduced pressure. The residue obtained was subjected to chromatography on silica gel to give brown crystals. { 1.4 g). XH-NMR (300MHz, CDC13) d: 1.18 (6H, d), 1.30 (3H, d), 2.08 (3H, s), 2.12 < 3H, s), 2.73-2.84. { lH, m), 3.65 (2H, s), 4.11-4.36 (3H, m), 4.17 (2H, s), 5.27 (2H, s), 7.00 (2H, t), 7.13-7.22 (5H, m) , 7.36-7.46. { lH, m), 7.52 (lH, br s), 7.62-7.82 (4H, q), 8.29 (1H, s).
EXAMPLE 3 Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- [4- (3-hydroxy-2-methylpropionylamino) phenyl] -4-oxothieno [2, 3-b] pyridine
the compound obtained in Example 2 (1.40 g) was dissolved in methanol (100 mL), and then potassium carbonate (2.0 g, 15 mmol) was added to the solution, followed by stirring at room temperature for 15 minutes. The reaction mixture was partitioned between ethyl acetate (200 mL) and distilled water (300 mL), and then the aqueous layer was extracted with ethyl acetate (100 mL). The combined extracts were washed with saline, and dried (Na2SO4), the solvent was distilled off under reduced pressure. The residue obtained was subjected to chromatography on silica gel from ether to give white crystals (0.95 g, 72%). mp 161-162 ° C. Elemental analysis for C37H3N30SF2 0.5H20 C (%) H (%) N (%) Calculated: 66.65; 5.74; 6.30 Found: 66.70; 5.52; 6.40 -? - NMR (300MHz, CDC13) d: 1.17 (6H, d), 1.18 (3H, d), 2.06 (3H, s), 2.67-2.78. { lH, m), 3.61 (2H, s), 3.57-3.84 (2H, m), 3.99- .08 (1H, m), 4.15 (2H, s), 5.52 (2H, s), 7.08 (2H, t ), 7.15 (5H, s), 7.44-7.54 (lH, m), 7.58. { 2H, d), 7.69 (2H, d), 8.46 (1H, s). FAB-Mass m / z 658 (MH) +.
Example 4 Using the compound obtained in Reference Example 29, the following compounds were obtained (Examples 4-1 to 4-3), in the same manner as in Example
Example 4-1:
Yield: 67% Pf 201-203 ° C
Example 4-2:
Yield: 58% Mp 135-137 ° C.
Example 4-3:
Performance: 75 'Pf 205-207 ° C
Example 5 Example 5-1: Production of 3-. { N-benzyl-N-methylaminomethyl) -4,1-dihydro-7- (2,6-difluorobenzyl) -2- [4- (2-hydroxyacetylamino) phenyl] -5-isobutyryl-4-oxothiene [2, 3- b] pyridine
The compound obtained in Example 4-1 (0.137 g) was dissolved in dichloromethane (1.0 mL), then, to 1 solution, trifluoroacetic acid (1.0 mL) was added dropwise with ice cooling. After stirring under the conditions of ice cooling for 1 hour, the reaction mixture was concentrated to dryness under reduced pressure, and then, the obtained residue was fractionated between chloroform (50 mL) and saturated aqueous sodium bicarbonate (50 mL). ), and then, the aqueous layer was extracted again with chloroform (10 mL). The combined organic layers were washed with saturated saline (30 mL). Then, the organic layer was dried (MgSO4), the solvent was distilled off under reduced pressure, and then, the obtained residue was chromatographed on silica gel and recrystallized from ethanol-ethyl acetate to give white crystalline powders ( 0.12 g, 95%).
Example 5-2: Production of 3- hydrochloride. { N-benzyl-N-methylaminomethyl) -4,7-dihydro-7- (2,6-difluorobenzyl) -2- [4- (2-hydroxyacetylamino) phenyl] -5-isobutyryl-4-oxothiene [2, 3- b] pyridine
The white crystalline powders obtained in Example 5-1, were dissolved in dichloromethane (1.0 mL), and then to this solution was added an ethanolic solution containing IN hydrogen chloride (10 mL), with ice cooling. The solvent was distilled under reduced pressure, and then, the residue was recrystallized from ethanol-ethyl acetate to give white crystalline powders (0.12 g, 84%). mp 197-199 ° C. Elemental analysis for C35H33N304SF2 HCl 2. 5H20 C (%) H (%) N (%) Calculated: 59.11; 5.53; 5.91 Found: 59.06; 5.25; 5.93 - H-NMR (300MHz, CDC13) d: 1.18 (6H, d), 2.10 (3H, s) «. 3.63 (2H, s), 3.72 (lH, br), 4.09-4.17 (lH, m), 4.16 (2H, s), 4.24 (2H, s), 5.24 (2H, s), 6.99 (2H, t) , 7.18-7.23 (5H, m), 7.35-7.45 (lH, m), 7.63. { 2H, d), 7.73 (2H, d), 8.25 (lH, s), 8.59 (lH, s).
Example 6 Using the compounds obtained in Example 4-2 and Example 4-3, the following compounds were obtained (Examples 6-1 to 6-2), in the same manner as in Example 5.
Example 6-1:
Yield: 76% Mw 192-194 ° C.
Example 6-2:
Yield: 81% Mp 193-195 ° C.
Example 7 Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-7- (2,6-difluorobenzyl) -2- (4-isobutyrylaminophenyl) -5- (2-hydroxy-2-methylpropionyl) ) -4-oxothieno [2, 3-b] pyridine
Amorphous brown crystals (0.13 g), obtained by repeating the method described in Reference Example 33, using the compound obtained in Reference Example 31-10, were hydrolysed with potassium acetate by the same method as described in Reference Example 34. The solid obtained was subjected to chromatography on silica gel to remove the compound obtained in Reference Example 34, and the by-product was recrystallized from methanol to give colorless crystalline powders (0.03 g). mp 170-172 ° C.
Elemental analysis for C37H37N304SF2 1 / 6H20 C (%) H (%) N (%) Calculated: 67.26; 5.69; 6.36 Found: 67.18; 5.74; 6.46"-H-NMR (300MHz, CDC13) d: 1.28 (6H, d), 1.49 (6H, s), 2.06 (3H, s), 2.51-2.60 (lH, m), 3.61 { 2H, s ), 4.13 (2H, s), 5.31 (2H, s), 7.01 (2H, t), 7.12-7.21 (5H, m), 7.37-7.47 (2H, m), 7.64 (2H, d), 7.74 {2H, d), 8.04 { LH, s), 8.35 { LH, s). IR (KBr): 3466,1669, 1499, 1313, 1075 cm "1.
Example 8 Production of 3-. { N-benzyl-N-methylaminomethyl) -4,7-dihydro-7- [2,6-difluorobenzyl] -2- (4-isobutyrylaminophenyl) -5- (2-hydroxy-2-methylpropionyl) -4-oxothiene [2 , 3-b] pyridine.
The compound obtained in Reference Example 34 (0.56 g) was dissolved in trifluoroacetic acid (10 mL) and stirred at room temperature for 1 hour. The reaction mixture was concentrated to dryness under reduced pressure, and the residue obtained was partitioned between dichloromethane (30 mL) and saturated aqueous sodium bicarbonate (60 mL), and then, the aqueous layer was extracted again with dichloromethane (10 mL). ). The combined organic layers were washed with saturated saline. { 30 mL) i After, the organic layer was dried (MgSO 4), the solvent was distilled under reduced pressure, to give amorphous brown crystals (0.42 g), which were subjected to chromatography on silica gel, to give crystals yellow (0.07 g, total recovery ratio as calculated from the compound obtained in Reference Example 31-10 12%). ^ - MR (300MHz, CDC13) d: 1.15 (3H, d), 1.26 (6H, d), 2.07 (3H, s), 2.53-2.62 (lH, m), 3.58 (2H, d), 3.66 (2H , d), 3.82 (1H, dd), 3.93 (1H, dd), 4.03 (1H, d), 4.22 (1H, d), 4.27-4.37. { 1H, m), 5.26 (2H, s), 6.99 (2H, t), 7.13-7.21 (5H, m), 7.36-7.46 (1H, m), 7.63 (2H, d), 7.67 (2H, d) 7.79 (1H, s), 8.30 (1H, s).
Example 9 Production of (R) -4,7-dihydro-2- [4- (3-t-butoxy-2-methylpropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N-benzyl) N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
To a solution of the compound obtained in Reference Example 29 (1.14 g, 2.0 mmol) in dichloromethane (20 mL), diisopropylamine (520 mg, 4 mmol) and (2R) -3-t-butoxy-2-acid were added. methylpropanoic acid (0.43 g, 3 mmol), followed by stirring with ice cooling. To the solution was added benzotriazol-1-yloxytrimethylaminophosphonium hexafluorophosphate (BOP reagent). { 1.33 g, 3 mmol). After the. stirring with ice cooling, for 1 hour, the solution was subsntly stirred at room temperature for 4 hours. The reaction mixture was concentrated to dryness under reduced pressure, and then the obtained residue was partitioned between water (50 mL) and chloroform (50 mL). The aqueous layer was extracted again with chloroform (10 mL). The combined extracts were washed with saline, and dried (MgSO4), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel, to give yellow powders
(1.11 g, 78%).
XH-NMR (300MHz, CDCl 3) d: 1.18 (6H, d), 1.25 (3H, d), 1.30 (9H, s), 2.62. { 3H, s), 2.63-2.71 (lH, m), 3.51 (1H, similar at), 3.61 (1H, dd), 3.64 (2H, s), 4.18 (2H, s), 4.18 (1H, quintuplete), 5.27. { 2H, s), 7.00 (2H, t), 7.14-7.22 (5H, m), 7.36-7.46 (1H,), 7.60 (2H, d), 7.76 (2H, d), 8.28 (1H, s), 9.00 (lH, s).
Example 10 Example 10-1: Production of (R) -4,7-dihydro-2- [4- (3-hydroxy-2-methylpropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N -benzyl-N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
The compound obtained in Example 9 (1.11 g,) was dissolved in trifluoroacetic acid (5 mL), under the conditions of ice cooling, and then, it was then stirred for 1 hour, the solution was allowed to warm to the temperature environment and stirred for another 12 hours. The reaction mixture was concentrated to dryness under reduced pressure, and then dissolved in methanol (20 mL) and again cooled with ice, and then a 5N solution of sodium hydroxide was added to reach a pH of 9.0. The reaction mixture was stirred for 30 minutes and then stirred at room temperature for 30 minutes. The reaction mixture was concentrated to dryness under reduced pressure at low temperature, and then the residue obtained was subjected to chromatography on silica gel. The yellow amorphous crystals obtained (0.83 g, 82%) were recrystallized from ether to give light yellow powdered crystals (0.69 g). mp 161-162 ° C. Elemental analysis for C37H37N304SF2 0.5H20 C (%) H (%) N (%) Calculated: 66.65; 5.74; 6.30 Found 66.47 5.73 6.10 -? - NMR (300MHz, CDC13) d: 1.18 (6H, d), 1.28 (3H, d), 2.11 (3H, s), 2.71 (lH, m), 3.65 (2H, s) , 3.83-3.85 (2H, m), 4.16 (1H, quint), 4.18 (2H, s), 5.27 (2H, s), 7.O0 (2H, t), 7.14-7.23 (5H, m), 7.36 -7.44. { lH, m), 7.64 (2H, d), 7.77. { 2H, d), 8.09 (1H, s), 8.28 (lH, s). FAB-Mass m / z 658 (MH) +
Example 10-2:
Production of (R) -4,7-dihydro-2- [4- (3-hydroxy-2-methylpropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N-benzyl-N-) hydrochloride methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
The title compound was obtained in the same manner as in Example 1. Mp 214-216 ° C.
Example 11 Example 11-1: Production of 4,7-dihydro-2- [4- (2-hydroxy-2-methylpropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N-benzyl-N -methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
To a solution of the compound obtained in Reference Example 29 (L14 g, 2.0 mmol) in dichloromethane, (30 mL) were added diisopropylethylamine (1.04 g, 8 mmol) and 2-hydroxyisobutanoic acid (0.416 g, 4 mmol), followed by by stirring under the conditions of ice cooling. To this solution was added benzotriazol-1-yloxytrimethylaminophosphonium hexafluorophosphate (BOP reagent) (1.76 g, 4 mmol). After stirring under the conditions of ice cooling for 1 hour, the solution was further stirred at room temperature for 4 days. The reaction mixture was concentrated to dryness under reduced pressure, and then the residue obtained was partitioned between water (50 mL) and chloroform (50 mL). The aqueous layer was extracted again with chloroform (10 mL). The combined extracts were washed with saline, and dried (MgSO4), the solvent was distilled under reduced pressure. The residue obtained was chromatographed on silica gel and recrystallized. from ether, to give crystals μilvei zad acerillos (0.56, 43%) Elemental Jólisis for C H N O SF 0.31 0 3? 37 3 4 Calculated C (%) H (%) N (%) 66.65; .74; 6.30 Ercrptrado 66.54; 5.49; 6.36 1H-NMR (300MHz, CDC13) d: 1.58 (6H, s), 2.10 (3H, s), 3. 05 (1H, brs), 3.64 (2H, s), 4.16 (2H, s ), 4.12-4.22 (lH, m), 5.23 (2H, s),
6. 99 (2H, t), 7.05-7.25 (5H, m), 7.34-7.44 (lH, m), 7.64 (2H, d),
7. 75 (2H, d), 8.25 (1H, s), 8.86 (1H, s).
Example 11-2: Production of 4,7-dihydro-2- [4- (2-hydroxy-2-methylpropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N-benzyl-N-) hydrochloride methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
The title compound was obtained in the same manner as in Example 1. Mp 213-215 ° C.
Example 12 Example 12-1 Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- [4- [(1-hydroxycyclopropyl) ) carbonylamino] phenyl] -4-oxothieno [2, 3-b] pyridine
To a solution of the compound obtained in Reference Example 29 (0.57 g, 1.0 mol) in dichloromethane (10 mL) were added diisopropylethylamine (0.52 g, 4 mmol) and 2-hydroxycyclopropanecarboxylic acid (0.204 g, 2 mmol), followed by stirring under the conditions of cooling with ice. To this solution was added benzotriazol-1-iloxitrisdimethylaminophosphonium hexafluorophosphate (BOP reagent)
(1.76 g, 4 mmol). After stirring under conditions of ice cooling for 1 hour, the solution was subsequently stirred at room temperature for 4 days. The reaction mixture was concentrated to dryness under reduced pressure, and then the residue obtained was partitioned between water (50 mL) and chloroform (50 mL). The aqueous layer was extracted again with chloroform (10 mL). The combined extracts were washed with saline, and dried (MgSO4) the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel and recrystallized from ether, to give yellow powdered crystals 80.27 g, 41%). XH-NMR (300MHz, CDC13) d: 1. l € -l.20 (2H, m), 1.18 (6H, d), 1.48-1.51 (2H, m), 2.09 (3H, s), 3.64 (2H , s), 3.95 (lH, br s), 4.14. { 2H, s), 4.12-4.19 (lH, m), 5.20 (2H, s), 6.99 (2H, t), 7.10-7.25 (5H, m), 7.34-7.46 (lH, m), 7.57 (2H, d), 7.70 (2H, d), 8.21 (1H, s), 8.82 (1H, s).
Example 12-2: Production of 3- hydrochloride. { N-benzyl-N-ethylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- [4- [(1-hydroxycyclopropyl) carbonylamino] phenyl] -4-oxothiene [2 , 3-b] pyridine
The title compound, white powdered crystals 80.12 g) were obtained in the same manner, as in Example 1. Solvent for recrystallization: ethanol: ether mp 220-222 ° C. Elemental analysis for C37H35N304SF2 HCl 0.5H20 C (%) H (%) N (%): Calculated: 63.37; 5.32; 5.99 Found: 63.35; 5.24; 5.82
Example 13 Example 13-1: Production of 47-dihydro-2- [4- (3-hydroxy-3-methylbutyrylamino) phenyl] -7- (2,6-ii ".uorcfca? Cyl) -3- (N- benzyl-N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
To a solution of the compound obtained in Reference Example 29 (1.14 g, 2.0 mmol) in dichloromethane (10 mL) were added diisopropylethylamine (1.04 g, 8 mmol) and 3-hydroxy-3-methylbutanoic acid (0.47 g, 4 mmol). ), followed by stirring under the conditions of ice cooling. To this solution was added benzotriazol-1-yloxytrimethylaminophosphonium hexafluorophosphate (BOP reagent) (1.76 g, 4 mmol). After stirring under the conditions of ice cooling for 1 hour, the solution was subsequently stirred at room temperature for 4 days. The reaction mixture was concentrated to dryness under reduced pressure, and then, the obtained residue was partitioned between water (50 mL) and chloroform (50 mL). The aqueous layer was extracted again with chloroform (10 mL). The combined extracts were washed with saline, and dried (MgSO 4), the solvent was distilled under reduced pressure. The obtained residue was subjected to chromatography on silica gel and recrystallized from ether, to give powdered yellow crystals (0.50 g, 37%). 1H-NMR (300MHz, CDC13) d: 1.17 (6H, d), 1.39 (6H, s), 2.11 (3H, s), 2.58 (2H, s), 3.12 (1H, br s), 3.65 (2H, s), 4.12-4.19 (lH, m), 4.18 (2H, s), 5.27 (2H, s), 7.00 (2H, t), 7.10-7.23 (5H, m), 7.32-7.44 (lH, m) , 7.61 (2H, d), 7.79 (2H, d), 8.24 (1H, s), 8.28 (1H, s).
Example 13-2: Production of 4,7-dihydro-2- [4- (3-hydroxy-3-methylbutyryl-1-amino) phenyl] -7- (2,6-difluorobenzyl) -3- hydrochloride (N -benzyl-N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
The title compound, powdered white crystals 80.42 g) were obtained in the same manner as in Example 1. Solvent for recrystallization: ethanol mp 216-218 ° C. Elemental analysis for C38H39N3? 4SF2 HCl C H20. { %) H. { %) N (%) Calculated: 62.84: 5.83; 5.79 Found: 62.70; 5.75; 5.82
Example 14 The following compounds (Examples 14-1 to 14-10) were produced by the same method as described in Examples 9, 11, 12 and 13, using the compound obtained in Reference Example 29, and also using several carboxylic acid compounds instead of, for example (2R) -t-butoxy-2-methylpropanoic acid, which was used in Example 9.
Example 14-1:
Yield: 46% Amorphous 1H-NMR (300MHz, CDC13) d: 1.18 (6H, d), 1.25 (3H, d), 1.30 (9H, s),
2. 11 (3H, s), 2.60 (lH, br), 3.51 (1H, similar at), 3.59-3.65 (lH, m), 3.65 (2H, s), 4.17 (lH, q), 4.18 (2H, s ), 5.27 (2H, s),
7. 00 { 2H, t), 7.12-7.22 (5H, m), 7.38-7.44 (lH, m), 7.60. { 2H, d), 7.75 (2H, d), 8.28 (1H, s), 9.00 (1H, s).
Example 14-2;
Performance: 47%
Mp 145-150 ° C.
Example 14-3:
Yield: 99% Mw 96-38 ° C.
Example 14-4:
Yield 57%: Mw 92-94 ° C.
Example 14-5:
Rendimi ent o: 71 'Pf 57-62 ° C
Example 14-6
Rendimi ent o: 92% Mw 79-81 ° C.
Example 14-7:
Yield: 97% Mp 91-96 ° c.
Example 14-8:
Yield: 91% Mw 75-80 ° C.
Example 14-9:
Rendimi ent o: 87% Pf 83-88 ° C.
Example 14-10:
Yield: 50% Mw 130-135 ° C.
Example 15 Using the compound obtained in Example 14, the following compounds were obtained (Examples 15-1 to 15-6), in the same manner as in Example 10.
Example 15-1:
Yield: 69% Mp 161-162 ° C.
Example 15-2
Yield: 94% Mw 153-155 ° C.
Example 15-3:
Yield: 62% Mp 224-226 ° C.
Example 15-4:
Yield: 56% Mw 230-232 ° C.
Example 15-5:
Rendimi at t o: 90% Mw 92-94 ° C.
Example 15-6:
Yield: 34% Mw 107-112 ° C.
Example 16 Example 16-1: Production of 3- (N-benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- (4-N'-ethoxyureidophenyl) 4-Oxothieno [2,3-b] pyridine To a solution of the compound obtained in Reference Example 29 (0.40 g, 0.7 mmol) in dichloromethane (15 mL) s added, triethylamine (0.20 mL, 1.43 mmol) and N, N'-carbonyldiimidazole (0.228 g, 1.41 mmol), followed by stirring under the conditions of an ice-cooling, then, the solution was allowed to warm to room temperature and then further stirred for 2.5 days, to the mixture O-methylhydroxylamine hydrochloride (0.59 g, 7.06 mmol) and triethylamine (0.98 mL, 7.03 mmol) were added with cooling with ice, while allowing the solution to return to room temperature, stirring for 1.5 hours. After dilution with water (50 mL), the reaction mixture was extracted with chloroform (50 mL). The aqueous layer was extracted again with chloroform (10 mL). The combined extracts were washed with saline, and dried (MgSO4), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel, to give amorphous yellow powders. . { 0.349 g, 77%).
^ -NMR (300MHz, CDC13) d: 1.19 (6H, d), 2.17 (3H, s), 3.72 (2H, brs), 3.83 (3H, s), 4.10-4.20 (lH, m), 4.22 (2H , brs), 5.28 (2H, s), 7.00 (2H, t), 7.15-7.24 (5H, m), 7.37-7.46 < 2H, m), 7.59 (2H, d) I 7.75 (2H, d), 7.83 (1H, br), 8.31 (lH, s).
Example 16-2: Production of 4,7-dihydro-2- [4-N'-methoxyureidophenyl) -7- (2,6-difluorobenzyl) -3- (N-benzyl-N-methylaminomethyl) -5-isobutyryl hydrochloride -4-oxothieno [2, 3-b] pyridine
The title compound, white amorphous powders (0.335 g), was obtained in the same manner as in Example 1. Solvent for recrystallization: ethyl acetate-ether Pf 225-230 ° C. mp 225-230 ° C. Elemental analysis for C35H34N40SF2 HCl 0.5H20 C (%) H (%) N (%) Calculated: 60.91; 5.26; 8.12 Found: 60.80; 5.07: 8.17
Example 17 Example 17-1: Production of (R) -4,7-dihydro-2- [4- (2, 3-dihydroxypropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N-benzyl) -N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
(R) - (+) -2,2-Dimethyl-1,3-dioxolan-4-carboxylic acid methyl ester (1.00 g, 6.24 mmol) was added to a 2N aqueous solution of potassium hydroxide, followed by low stirring. the conditions of a cooling with ice for 3 hours. After neutralization with hydrochloric acid, the solution was precipitated and extracted with ethyl acetate (50 mL) to give, acid (R) - (+) -2, 2-dimethyl-1-1, 3-dioxolan-4 -carboxylic as colorless amorphous powders (0.72 g). To a solution of the compound obtained in Reference Example 29 (0.572 g, 1.0 mmol) in dichloromethane (5 mL) were added diisopropylethylamine (0.04 g, 8 mmol) and the (R) - (+) - 2, 2-dimethyl-l, 3-dioxolan-4-carboxylic acid obtained (0.292 g) , 2 mmol), followed by stirring under the conditions of ice cooling. to this solution was added benzotriazol-1-yloxytrimethylaminophosphonium hexafluorophosphate (BOP reagent) (0.885 g, 2 mmol). After stirring under the conditions of ice cooling for 1 hour, the solution was further stirred at room temperature for 4 days. The reaction mixture was concentrated to dryness under reduced pressure, and then, the obtained compound was partitioned between water (50 mL) and chloroform (50 mL). The aqueous layer was extracted again with chloroform (10 mL). The combined extracts were washed with saline, and dried (MgSO 4), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel to give colorless amorphous powders (0.5 g), which were then dissolved in trifluoroacetic acid (10 mL) and stirred at room temperature for 16 hours. The reaction mixture was concentrated to dryness under reduced pressure and treated with an alkali, after which it was partitioned between chloroform (50 mL) and water (50 mL), and then, the aqueous layer was extracted again with chloroform ( 10 mL). The combined extracts were washed with saline, and dried (MgSO4), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel to give 0.5 g of amorphous colorless powder (76%). • -H-NMR (300MHz, DMSO-de) d: 1.09 (6H, d), 1.95. { 3H, s), 3.51 (2H, br), 3.55-3.72 (2H, m), 4.01-4.08 (4H, m), 4.84 (lH, t), 5.63 (2H, brs), 5.80 (lH, d) , 7.15-7.24 (7H, m), 7.49-7.57 (lH, m), 7.66 (2H, d), 7.84 (2H, d), 8.53 (lH, s), 9.82 (lH, s).
Example 17-2: Production of (R) -4,7-dihydro-2- [4- (2, 3-dihydroxypropionylamino) phenyl] -7- (2,6-difluorobenzyl) -3- (N-benzyl) hydrochloride -N-methylaminomethyl) -5-isobutyryl-4-oxothieno [2, 3-b] pyridine
The title compound, white powdered crystals (0.43 g) were obtained in the same manner as in Example 1. Solvent for recrystallization: ether-ethanol Mp 146-148 ° C.
Example 18 Production of 4,7-dihydro-2- (4-N'-hydroxy-N 'methylureidophenyl) -7- (2,6-difluorobenzyl) -3- (N-benzyl-N-methylaminomethyl) -5-isobutyryl -4-oxothieno [2, 3-b] pyridine
To a solution of the compound obtained in Reference Example 29 (1.0 g, 1.75 mmol) in dichloromethane. { 40 mL) were added triethanolamine (0.49 mL, 3.50 mmol) N, N'-carbonyldiimidazole (0.567 mg, 3.50 mmol), followed by stirring under the conditions of ice-cooling, then, the solution was allowed to warm to the At room temperature and subsequently stirred for 17 hours, N-methylhydroxylammonium chloride (730 mg, 8.75 mmol) and triethylamine (1.23 mL, 8.75 mmol) were added to the mixture with ice cooling, while the solution was allowed to warm to room temperature. the room temperature was stirred for 5 hours. The reaction mixture was partitioned between chloroform (300 mL) and aqueous sodium bicarbonate (saturated, 200 mL), and then, the organic layer was washed again with saline (200 mL). After the organic layer was dried (MgSO), the solvent was distilled under reduced pressure. The residue obtained was subjected to chromatography on silica gel to give yellow amorphous powder (0.38 g, 34%). - •• H-NMR (300MHz, CDC13) d: 1.18 (6H, d), 2.15 (3H, s), 3.26 (3H, s), 3.71. { 2H, s), 4.19 (2H, s), 5.25 (2H, s), 7.00. { 2H, t), 7.22- 7.26 (5H, m), 7.41 (1H, m), 7.49 (2H, d), 7.60 (2H, d), 8.06 (
1H, s), 8.26 (1H, s). Elemental analysis for C35H34N404SF2 0. 8H2O C (%) H (%) N (%) Calculated: 63.78; 5.44; 8.50 Found: 63.73; 5.24; 8.41
Example 19 Production of 2- [4 - [(l-acetoxycyclopropyl) carbonylamino] phenyl] -3- (N-benzyl-N-methylaminophenyl) -5-benzoyl-7- (2,6-difluorobenzyl) -4, 7- dihydro-4-oxothieno [2, 3-b] pyridine
To a solution of the compound obtained in Reference Example 28 (0.47 g, 0.7 mmol) and triethylamine (0.08 g, 0.8 mmol) in dichloromethane (10 mL), was added 1-acetoxycyclopropanecarbonyl chloride (0.13 g, 0.8 mmol) with Upon ice cooling, the mixture was stirred at 0 ° C for 30 minutes and at room temperature for 30 minutes. The reaction mixture was diluted with chloroform (20 mL) and the solution was washed with aqueous sodium bicarbonate (saturated, 20 mL), and brine. { 20 mL). After the organic layer was dried (MgSO 4), the solvent was distilled under reduced pressure. The residue was chromatographed on silica gel to give yellow amorphous powders (0.34 g, 66%). 1H-NMR (300MHz, CDC13) d: 1.22 (2H, dd), 1.68 (2H, dd), 2.12 (3H, s), 2.21 (3H, s), 3.64 (2H, s), 4.13 (2H, s) ), 5.28 (2H, s), 7.01 (2H, t), 7.17-7.23 (5H, m), 7.37-7.44 (3H, m), 7.51-7.56 (1H, m), 7.60 (2H, d), 7.81 (2H, d), 7.87-7.90 (3H, m), 7.94 (1H, s). FAB-Mass m / z 732 (MH) +
Example 20 Using the compound obtained in the Example of
Reference 28, the following compound was obtained, Example 20-1 in the same manner as in Example 19
Example 20-1:
Yield: 80% 1H-NMR (300MHz, CDC13) d: 1.77 (6H, s), 2.12 (3H, s), 2.17 (3H, s), 3.63 (2H, s), 4.13. { 2H, s), 5.29. { 2H, s), 7.01 (2H, t), 7.15-7.23 (5H, m), 7.38-7.45 (3H, m), 7.51-7.56 (1H, m), 7.64. { 2H, d), 7.85 (2H, d), 7.88-7.90 (3H, m), 7.94 (1H, s). FAB-Mass m / z 734 (MH) +
Using the compound obtained in Reference Example 28, the following compound was obtained, Example 20-2 in the same manner as in Example 19
Example 20-2;
Yield: 84% -? - NMR (300MHz, CDC13) d: 1.25 (3H, d), 1.30 (9H, s), 2.10 (3H, s), 2.65-2.67 (lH, br m), 3.51 (2H , t), 3.60 (2H, s), 4.12 (2H, s), 5.28 (2H, s), 7.00 (2H, t), 7.16-7.23 (5H, m), 7.37-7.42 (3H, m), 7.50-7.53 (1H, m), 7.61 (2H, d), 7.80 (2H, d), 7.89 (2H, d), 7.9 (1H, s), 9 .01 (1H, s). FAB-Mass m / z 748 (MH) +
Example 21 Production of 3- (N-benzyl-N-methylaminomethyl) -5-benzoyl-7- (2,6-difluorobenzyl) -4,7-dihydro-2- [4- [(1-hydroxycyclopropyl) carbonyl] phenyl ] -4-oxothieno [2, 3-b] pyridine
A mixture of the compound obtained in Example 19
(0.24g, 0.33 mmol) and sodium hydroxide (0.07 mL) in ethanol
(8 mL) was stirred at room temperature for 1 hour. Then, the solvent was distilled under reduced pressure, the residue obtained was dissolved in chloroform (30 mL) and the solution was washed with aqueous sodium bicarbonate (Saturated,
L) and brine (20 mL). After, the organic layer was dried
(MgSO), the solvent was distilled under reduced pressure and the residue was recrystallized from chloroform-ether, to give pale yellow powders (0.17 g, 75%). mp 186-188 ° C. XH-NMR (300MHz, CDC13) d: 1.15 (2H, dd), 1.44 (2H, dd), 2.05 (3H, s), 3.56 (2H, s), 4.01 (2H, s), 4.56. { 1H, br s), 5.24 (2H, s), 7.00 (2H, t), 7.14-7.22 (5H, m), 7.41 (3H, t), 7.55 (2H, d), 7.55 (1H, s), 7.70 (2H, d), 7.88 (2H, d), 7.90 (1H, s), 8.88 (1H, s). Elemental analysis for C4OH33N304SF2 1.0H2O C (%) H (%) N (%) Calculated: 67.88; 4.98; 5.34 Found 67.75; 4.70; 5.90 FAB-Mass m / z 690 (MH) +
Example 22 Production of 3- (N-benzyl-N-methylaminomethyl) -5-benzoyl-7- (2,6-difluorobenzyl) -4,7-dihydro-2- [4-. { 2-hydroxy-2-methylpropionylamino) phenyl] -4-oxothieno [2, 3-b] pyridine
Using the compound obtained in Example 20-1, the title compound was obtained, in the same manner as in Example 21. Solvent for recrystallization: chloroform-ether mp 222-223 ° C. 1H-NMR (300MHz, CDC13) d: 1.57 (6H, s), 2.09 (3H, s), 2.50 (1H, s>, 3.59 {2H, s), 4.10 (2H, s), 5.28. { 2H, s), 7.01 (2H, t), 7.16-7.25. { 5H, m), 7.38-7.44 (3H,), 7.51-7.56 (1H, m), 7.67 (2H, d), 7.82 (2H, d), 7.89 (2H, d), 7.93 (1H, s), 8.82 (1H, s). FAB-Mass m / z 692 (MH) +
Example 23 Production of (R) -3- (N-benzyl-N-methylaminomethyl) -5-benzoyl-7- (2,6-difluorobenzyl) -4,7-dihydro-2- [4- [. { 3-hydroxy-2-methylbutyrylamino) phenyl] -4-oxothieno [2, 3-b] pyridine
Using the compound obtained in Example 20-2, the title compound was obtained in the same manner as in Example 10. Solvent for recrystallization: chloroform-ether mp 145-146 ° C. XH-NMR (300MHz, CDC13) d: 1.25 (3H, d), 2.07 (3H, s), 2.63-2.70 (1H, m), 2.84 (1H, br s), 3.57. { 2H, s), 3.78-3.81 (2H, m), 4.08 (2H, s), 5.27 (2H, s), 7.00 (2H, t), 7.17-7.20 (5H, m), 7.37-7.43. { 3H, m), 7.51-7.56 (1H, m), 7.61 (2H, d), 7.77 (2H, d), 7.89 (2H, d), 7.94 (1H, s), 8.31 (1H, br s).
FAB-Mass m / z 692 (MH) +
Preparation Example 1 Using 100 mg of the compound produced in Example 1-2, 165 mg of lactose, 25 mg of corn starch, 4 mg of polyvinyl alcohol and 1 mg of magnesium stearate, tablets are produced by a conventional method.
Preparation Example 2 The compound produced in Example 1-2 (5 g) is dissolved in distilled water for injection, to make a total volume of 100 mL. This solution is aseptically filtered through a 0.22 μm filtration membrane (produced by Sumitomo Electric Industries, Ltd. or Sartorius) and distributed to 2 mL sterile washed ampule, followed by freeze dehydrate by a conventional method, to give a injectable preparation of 100 mg / vial dehydrate by freezing.
Preparation Example 3 Using 100 mg of the compound produced in Example 3, 165 mg of lactose, 25 mg of corn starch, 4 mg of polyvinyl alcohol and 1 mg of magnesium stearate, tablets are produced by a conventional method.
Preparation Example 4 The compound produced in Example 3 (5 g), is dissolved in distilled water for injection, to make a total volume of 100 mL. This solution is aseptically filtered through a 0.22 μm filtration membrane (produced by Sumitomo Electric Industries, Ltd. or Sartorius) and distributed to 2 mL per sterile ampule, followed by dehydration by freezing by a conventional method, to give an injectable preparation of 100 mg / vial dehydrated by freezing.
Preparation Example 5 (1) the compound produced in Example 1-2 5 g (2) Lactose / crystalline cellulose (particles) 330 g (3) D-mannitol 29 g (4) 20 G low substitution hydroxypropyl cellulose (5) ) Talc 25 g (6) Hydroxypropyl cellulose 50 g (7) Aspartame 3 g (8) Dipotassium glycyrrhizinate 3 g. (9) Hidoxypropylmethyl cellulose 2910 30 g (10) Titanium oxide 3.5 g (11) Fiery yellow sesquioxide 0.5 g (12) silicic light anhydride 1 g components (1), (3), (4), (5) , (6), (7) and (8) are suspended or dissolved in purified water and coat the nuclear particles (2), to give a fine base fabric, which is then coated, subsequently with, the components (9). ) to (11) to give coated fabrics, which are then mixed with the composite (12) to give 500 g of 1% of composite tissues. These tissues are divided to 500 mg folded tissues.
Experimental Example 1 Preparation of l25pI-leuprorelin To a tube containing 10 μl of aqueous solution 3xlO-M of leuprorelin and 10 μl of 0.01 mg / mL of lactoperoxidase, 10 μl (37 MBq) of a solution of Na125I was added. After stirring, 10 μl of H202 was added at 0.001%, the reaction was carried out at room temperature for 20 minutes. The reaction was stopped by the addition of 700 μl of a 0.05% solution of TFA (trifluoroacetic acid), followed by purification by reverse phase HPLC. The HPLC conditions used are shown below. I-leuprorelin was eluted at the retention time of 26 to 27 minutes.
Column: TSKgel ODS-80 ™ (TM indicates a registered trademark, same applies below) CTR (4.6 nm x 10 machine controller) Eluents: Solvent A (0.05% TFA) Solvent B (CH3CN 'at 40% -TFA 0.05%) 0 minutes (100% solvent A) - 3 minutes (100% solvent A) - 7 minutes (50% solvent A + 50% solvent B) - 40 minutes. { 100% solvent B) Evasion temperature: Ambient temperature Speed of elusion: 1 mL / min
Experimental Example 2 Preparation of a rat pituitary anterior lobe membrane fraction containing receptors
GnRH The anterior lobes of the pituitary glands were isolated from forty Wistar rats (8 weeks of age, males), and washed with homogenized buffer [25 mM Tris (tris [hydroxymethyl) aminomethane) -HCl, sucrose 0.3M, EGTA lmM ( glycol ether-ether diamine- N, N, N ', N' -tetracetic acid), PMSF 0.25 mM. { phenylmethylsulfonyl fluoride), 10 U / mL of aprotinin, 1 mg / mL of pepestatin, 20 mg / mL of leupéptin, 100 mg / mL of phosphoramidon, 0.03% sodium azide, pH 7.5]. the pituitary tissue was floated in 2 mL of the buffered-homogenate and homogenized using a Polytron homogenizer. The homogenadp was centrifuged at 700 x g for 15 minutes. The supernatant was recovered in an ultra centrifuge tube and centrifuged at 100,000 x g for 1 hour to provide a pellet of the membrane fraction. This pellet was suspended in 2 mL of the assay buffer [25 mM tris-HCl, 1 mM EDTA. { ethylenediaminetetracetic acid), 1% BSA (bovine serum albumin), 0.25 mM PMSF, 1 mg / mL pepestatin, 20 mg / mL leupeptin, 100 mg / mL phosphoramidon, 0.03% sodium azide, pH 7.5 ) and the suspension was centrifuged at 100,000 xg for 1 hour. The membranous fraction recovered as a pellet was suspended in 10 mL of assay buffer, divided into portions, preserved at -80 ° C and thawed when necessary.
Experimental Example 3 Preparation of the membranous fraction of CHO (ovaries from Chinese hamsters) containing the human GnHR receptor CHO cells expressing the GnRH receptor (EP-A-678577) (109 cells) were suspended in phosphate buffered saline supplemented with 5 nM EDTA (ethylenediaminetetracetic acid) (PBS-EDTA) and centrifuged at 100 xg for 5 minutes. To the cell pellets, 10 mL of a cellular homogenous buffer (NaHC03 lOmM, 5 mM EDTA) was added, followed by homogenization using the Polytron homogenizer. After centrifugation at 400 x g for 15 minutes, the supernatant was transferred to an ultra centrifugation tube and centrifuged at 100,100 x g for 1 hour to give a precipitate of the membranous fraction. This precipitate was suspended in 2 mL of a test buffer and centrifuged at 100,000 x g for 1 hour. The membranous fraction recovered as a precipitate was again suspended in 20 mL of the assay buffer, distributed, and stored at -80dC before use was thawed.
EXPERIMENTAL EXAMPLE 4 Determination of the binding inhibition of 125I-leurporelin The membranous fractions of human and rat prepared in Experimental Examples 2 and 3 were diluted with the assay buffer to give a dilution of 200 mg / mL, the which was distributed to 188 mL per tube. Where the membranous fraction of the rat pituitary anterior lobe was used, 2 ml of a 0.1 mM solution of the compound in 60% DMSO (dimethyl sulfoxide) and 10 μl of 38 nM 125I-leuprorelin were added to each tube simultaneously. Where the cell membrane fraction of the CHO was used with the expressed human GnRH receptors, 2 mL of a 2 mM solution of the compound in 60% DSO and 10 μl of 38 nM 125I-leuprorelin were added to each tube simultaneously. To determine the maximum amount of agglutination, a reaction mixture of 2 μl of 60% DMSO and 10 μl of 38 nM 125I-leuprorelin was prepared. To determine the amount of non-specific binding, a reaction mixture of 2 μl of 100 μM of leuprorelin in 60% solution in DMSO of 38 nM 125I-leuprorelin was prepared.
Where the membranous fraction of the anterior lobe of the bovine or rat pituitary was used, the reaction was conducted at 4 ° C for 90 minutes. Where the membranous fraction of CHO with expressed human GnRH receptors was used, the reaction mixture was carried out at 25 ° C reduced pressure 60 minutes. After each reaction, the reaction mixture was aspirated and filtered through a Whatman glass filter (GF-F) treated with polyethylene diamine. After filtration, the radioactivity of the remaining 125I-leuprpreline was measured on the filter paper, with a counter of y. The expression (TB-SB) / (TB-NSB) xlOO was calculated (where SB = radioactivity with the aggregate compound, TB = determined maximum radioactivity, NSB = determined non-specific radioactivity) to find the inhibition of the binding speed ( %) of each test compound. In addition, the rate of inhibition was determined by varying the concentration of the test substance and 50% of the inhibitory concentration (IC50 value) of the compound was calculated from the Hill plot. The results are shown below.
Inhibition of agglutination value IC 50 Speed test compound (%) (μM) Rat (lμM) Human (20 μM) Human Rat
Comp. of Ex .1-2 96 102 0.06 0.0001 Comp. of Ex. 3 | 62 NT 0.6 0.0002
NT: not measured
EXPERIMENTAL EXAMPLE 5 Suppression of LH from blood in castrated monkeys The compound produced in Example 1-2 was orally administered to castrated male cynomolgus monkeys (Macaca fascicularis), and the LH of the blood was quantified. The male cynomolgus monkeys, used had 3 years 8 months, 7 years 7 months of age at the time of experimentation, have been neutered for more than half a year prior to the examination. To the test animals [n = 2; compound (1) and compound [2) 1, they were given 30 mg / kg (3 mL / kg) of the compound suspended in 0.5% methyl cellulose at a final concentration of 1%, by oral administration, and the control animals (n = 3, control (1), control (2) and control (3)] were given 3 mL / kg of 5% methyl cellulose dispersant only, by oral administration, at 24 hours and immediately before administration. administration and at 2, 4, 6, 8, 24, and 48 hours after the administration, blood was collected for heparinized plasma samples, via the femoral vein and immediately stored under freezing conditions.
Plasma LH concentrations were determined by a bioassay using mouse testicular cells. Testicular cells were collected from male BALB / C mice (8 to 9 weeks of age) and washed three times with 1 mL of modified Dulbecco's Eagle's medium (DMEM-H) containing 20 mM HEPES and 0.2% BSA. testis After incubation at 37 ° C for 1 hour, the cells were passed through a nylon mesh filter (70 μm) and distributed to test tubes at 8 x 10 5 cells / tube. After, that the cells were washed twice with 0.4 mL of DMEM-H, 0.4 mL of a solution of DMEM-H containing, any Equine LH (Sigma Company) was added, as the standard LH, or monkey plasma, diluted previously up to 1,000 folds, as the test sample, followed by the reaction at 37 ° C for 2 hours. The concentration of testosterone in the culture supernatant was determined by a radioinone test (CIS Diagnostics Company), and the LH concentrations in the plasma of the test monkey were calculated from the standard curve for the equine standard LH.
The results are given together in Figure 1. The indicated compound is the compound obtained in Example 2-1. For control (1), control (2), and control (3), changes over time in the LH concentrations in each animal were expressed as percentage ratios to the respective reference values, which comprise the LH concentrations immediately before administration in each control animal (Cynomolgus monkeys). Similarly, for compound (1) and compound (2), changes over time in the concentrations of LH in each animal (cynomolgus monkeys) that received the compounds of Example 1-2 are expressed as ratios of% to respective reference values, which comprise the LH concentrations immediately before the administration of the compound. The administration time was defined as zero (0), and the hours before and after administration are shown by minus and plus signs respectively.
INDUSTRIAL APPLICABILITY The compound of the present invention possesses excellent gonadotropin releasing hormone antagonizing activity. It is also good in its ability to absorb itself and pharmacokinetics. With low toxicity, it is also excellent in safety.
The compound of the present invention can therefore be used as a prophylactic or therapeutic agent for hormone-dependent diseases etc. Specifically, it is effective as a prophylactic or therapeutic agent for sex hormone-dependent cancers (e.g., prostate cancer,, uterine cancer, breast cancer, pituitary tumor), prostatic hypertrophy, hysteromyoma, endometriosis, precocious puberty, amenorrhea syndrome, syndrome of the multiocular ovary, pimples etc., or as a regulator of pregnancy (for example, contraceptive), remedy against infertility or regulator of menstruation. It is also effective as an animal estrus regulator, meat quality enhancer for feed or animal growth regulator in the field of animal husbandry, and as a promoter of roe deposition in the field of the fishing industry.
It is noted that in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Having described the invention as above, property is claimed as contained in the following:
Claims (24)
1. A compound of the formula: characterized in that, R 1 represents a C 1-7 alkyl group, which may be substituted, a C 3-7 cycloalkyl group, which may be substituted, an alkoxyamino group of C1-6, which may be substituted or a hydroxyamino group, which may be substituted; and R2 represents an alkyl group of C7-7, which may be substituted or a phenyl group, which may be substituted; when R1 is an unsubstituted C1-7 alkyl group, then R 2 is a substituted C 1-7 alkyl group or a substituted phenyl group, or a salt thereof.
2. A compound of claim 1 or a salt thereof, characterized in that, R1 is (1) an alkyl group, which may be substituted by 1 to 5 substituents selected from the group consisting of (i) hydroxy, (ii) acyloxy of C1-7, (iii) amino, which may be substituted by 1 to 2 substituents selected from the group consisting of C6-6-carbonyl alkoxy, benzyloxycarbonyl, Ci-3 acyl, C1-3 alkylsulfinyl, and C-alkyl ? -3, (iv) Ci-3 alkoxy, which may be substituted by 1 to 3 substituents selected from the group consisting of C3-7-cycloalkoxy-carbonyl and C1-3-alkoxy and (v) C-alkoxy? _6-carbonyl, (2) a cycloalkyl group of C3-7 / which may be substituted by 1 to 3 substituents selected from the group consisting of (i) hydroxy, (ii) C1-7 acyloxy, (iii) amino, which may be substituted by 1 or 2 substituents selected from the group consisting of C?-6-carbonyl alkoxy, benzyloxycarbonyl, C?-3 acyl, C 1-3 alkylsulfonyl and C 1-3 alkyl, (iv) C 1-10 alkoxy , which may be substituted by 1 to 3 substituents selected from the group consisting of C3-7-cycloalkyloxy-carbonyl and C1-3-alkoxy and (v) C6-6-carbonyl-alkoxy, (3) an alkoxyamino group of C? -β, which may be substituted by 1 to 5 substituents selected from the group consisting of (i) hydroxy, (ii) C 1-7 acyloxy, (iii) amino, which may be to be substituted by 1 or 2 substituents selected from the group consisting of C?-6-carbonyl alkoxy, benzyloxycarbonyl, C 1-3 acyl, C 1-3 alkylsulfonyl and C? _3 alkyl, (iv) C 1-10 alkoxy , which may be substituted by 1 to 3 substituents selected from the group consisting of C3-7-cycloalkyloxycarbonyl and C1-3alkoxy and (v) C6-6-carbonyl alkoxy, or (4) a hydroxyamino group, which may be substituted by 1 or 2 substituents selected from the group consisting of (i) C1-7 acyloxy, (ii) amino, which may be substituted by 1 or 2 substituents selected from the group consisting of C-alkoxy? _6-carbonyl, benzyloxycarbonyl, acyl of C? _, Alkylsulfonyl of C1-3 and alkyl of C1-3, (iii) C1-10 alkoxy, which may be substituted by 1 to 3 substituents selected from the group consisting of C3-7-cycloalkyloxycarbonyl and C1-3alkoxy and (iv) C6-6alkyl; and R 2 is (1) a C 1-7 alkyl group which may be substituted by 1 to 5 substituents selected from the group consisting of (i) hydroxy, (ii) acyloxy, (iii) amino, which may be substituted by 1 or 2 substituents selected from the group consisting of C 1-6 alkoxycarbonyl, benzyloxycarbonyl, C 1-3 acyl, C 1-3 alkylsulfonyl and C 3-3 alkyl, (iv) C 1-10 alkoxy which may be to be substituted by 1 to 3 substituents selected from the group consisting of C3-7-carbonyl cycloalkyloxy and C1-3 alkoxy and (v) C6-6-carbonyl alkoxy, or (2) a phenyl group, which may be to be substituted by 1 to 5 substituents selected from the group consisting of halogen, C? _3 alkyl and C1-3 alkoxy.
3. A compound of claim 1 or a salt thereof, characterized in that R1 is an alkyl group of Ci-7, which may be substituted or a cycloalkyl group of C3-7 / which may be substituted.
4. A compound of claim 1 or a salt thereof, characterized in that, R1 is a substituted, branched C3_7 alkyl group, or a substituted C3_7 cycloalkyl group.
5. A compound of claim 1 or a salt thereof, characterized in that, R1 is an alkyl group of Ci-7, substituted by hydroxy, or a cycloalkyl group of C3-7 substituted by hydroxy.
6. A compound of claim 1 or a salt thereof, wherein R 1 is a substituted C 3-7 cycloalkyl group.
7. A compound of claim 1 or a salt thereof, characterized in that, R 1 is a cyclopropyl group, which may be substituted by hydroxy.
8. A compound of claim 1 or a salt thereof, characterized in that R2 is a branched C3-7 alkyl group, which may be substituted.
9. A compound of claim 1 or a salt thereof, characterized in that, R 2 is a phenyl group, which may be substituted.
10. A compound of claim 1 or a salt thereof, characterized in that R2 is a phenyl group.
11. A compound of claim 1 or a salt thereof, characterized in that, R1 is a cycloalkyl group of C3-7 and R2 is an alkyl group of Ci-β.
12. A compound of claim 1 or a salt thereof, characterized in that, R1 is (l) a C1-4 alkyl group, substituted by 1 or 2 hydroxy, (2) a C3-7 cycloalkyl group substituted by hydroxy, or (3) a C1-3 alkoxyamino group; and R2 is an isopropyl group or a phenyl group,
13. A compound of claim 1 or a salt thereof, characterized in that, R1 is (1) an alkyl group of C? -7, which may be substituted by 1 or 2 substituents de-selected from the group consisting of hydroxy, C? -3-carbonyloxy, amino, benzyloxycarbonylamino, C? _3 alkoxy, C? -3-C3-alkoxy alkoxy and C? _3-carbonyl alkoxy, (2) a C3_7 cycloalkyl group, which can to be substituted by a hydroxy, or a C?-3-varbonyloxy alkyl, or (3) an alkoxyamino group of Ci--3; and R2 is (1) an isopropyl group, which may be substituted by a hydroxy or (2) a phenyl group.
14. 3- (N-Benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- (4-cyclopropanecarbonylaminophenyl) -4-oxothiene [2, 3-b] pyridine or a salt thereof.
15. 3- (N-Benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (2,6-difluorobenzyl) -2- [4- (3-hydroxy-2-methylpropionylamino) phenyl] -4 -oxotiene [2, 3-b] pyridine or a salt thereof.
16. 3- (N-Benzyl-N-methylaminomethyl) -4,7-dihydro-5-isobutyryl-7- (-2,6-difluorobenzyl) -2- [4- [(1-hydroxycyclopropyl) carbonylamino] phenyl] -4 -oxotiene [2, 3-b] pyridine or a salt thereof.
17. 3- (N-benzyl-N-methylaminomethyl) -5-benzoyl-7- (2,6-difluorobenzyl-4,7-dihydro-2- [4- [(1-hydroxycyclopropyl) carbonylamino] phenyl] -4-oxothiene [2, 3-b] pyridine or a salt thereof.
18. A process for the production of a compound of claim 1 or a salt thereof, characterized in that it comprises the reaction of a compound of the formula: characterized in that R2 represents a C1-7 alkyl group, which may be substituted or a phenyl group, which may be substituted, or a salt thereof, with i) a compound of the formula: RlaCOOH wherein Rla represents a C 1-7 alkyl group, which may be substituted or a C 1-3 cycloalkyl group, which may be substituted, or a salt thereof or a reagent derived therefrom; or ii) carbonyldiimidazole, phosgene or a chloroformate, followed by the reaction with a compound of the formula: RlbH wherein Rlb represents an alkoxyamino group of C? -β, which may be substituted or a hydroxyamino group, which may be substituted , or a salt thereof.
19. A process for producing a compound of claim 3 or a salt thereof, characterized in that it comprises the reaction of a compound of the formula: wherein R represents an alkyl group of C? _7, which may be substituted or a phenyl group, which may be substituted, or a salt thereof, with a compound of the formula: RlaCOOH wherein Rla represents a C 1-7 alkyl group, which may be substituted or a C 3-7 cycloalkyl group, which may be substituted, or a salt thereof or a reagent derived therefrom.
20. A pharmaceutical composition, characterized in that it comprises a compound of claim 1 or a salt thereof.
21. A pharmaceutical composition of claim 20, characterized in that it is for antagonizing the gonadotropin releasing hormone.
22. A pharmaceutical composition of claim 21, characterized in that it is for preventing or treating a sex hormone dependent disease.
23. A method for antagonizing gonadotropin releasing hormone, in a mammal in need thereof, characterized in that it comprises administering to said mammal an effective amount of a compound of claim 1 or a salt thereof with a pharmaceutically acceptable excipient. , carrier or diluent.
24. The use of a compound of claim 1 or a salt thereof to manufacture a pharmaceutical composition for antagonizing the gonadotropin releasing hormone.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/181263 | 1998-06-26 | ||
JP10/333004 | 1998-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00011184A true MXPA00011184A (en) | 2001-09-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU764019B2 (en) | Thienopyrimidine compounds, their production and use | |
US6187788B1 (en) | Condensed-ring thiophene derivatives, their production and use | |
JPH09169768A (en) | Thienopyrimidine derivative, its production and use | |
US6048863A (en) | Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use | |
US6262267B1 (en) | Thienopyridine compound | |
US6297379B1 (en) | Thienopyrimidine compounds, their production and use | |
US20040180873A1 (en) | Thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | |
AU2002337035A1 (en) | Thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | |
US6329388B2 (en) | Thienopyridine compounds, their production and use | |
US6297255B1 (en) | Thienopyridine compounds, their production and use | |
MXPA00011184A (en) | Thienopyridine compounds, their production and use | |
JP3854648B2 (en) | Condensed thiophene derivative, production method and use thereof | |
JP3028486B1 (en) | Thienopyridine derivatives, their production and use | |
ZA200006601B (en) | Thienopyridine compounds, their production and use. | |
JP4652520B2 (en) | Thienopyrimidine compound, production method and use thereof | |
CZ20004706A3 (en) | Thienopyridine compounds, process of their preparation and use | |
JPH09169766A (en) | Thienpyridine, its production and use thereof | |
JPH1036373A (en) | Thienopyridine derivative, its production and use |